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Résumé 
Le virus de l’hépatite C (VHC) est un agent causateur de maladies du foie important 
responsable d’une pandémie affectant près de 180 millions d’individus mondialement. 
L’absence de symptômes dans les premières années d’infection entraîne des diagnostics tardifs 
qui empêchent la prise en charge rapide des patients avant l’apparition d’une fibrose et, dans 
près de 16 % des cas d’infection, d’une cirrhose. 
 
 En exploitant les interactions protéine-protéine membranaires, des essais utilisant la 
technologie BRET, dans les cellules vivantes, ont été précédemment optimisés afin d’établir le 
réseau complet des interactions du VHC. En utilisant les fondements de cette étude, un essai à 
haut débit dans les cellules vivantes a été réalisé pour identifier de nouveaux composés anti-
VHC ciblant une nouvelle interaction NS3/4A-NS3/4A.  Approximativement 110,000 petites 
molécules ont été criblées pour leurs effets sur l’homodimérization de NS3/4A et ont été 
classées par rapport à leur spécificité et à leur puissance contre le VHC. Au terme de cette 
étude, UM42811 a été identifié comme un activateur potentiel de l’interaction NS3/4A-
NS3/4A offrant une activité antivirale prometteuse dotant une excellente fenêtre 
thérapeutique.  Par la suite, un séquençage exhaustif des virus, soumis à un traitement de 
UM42811, a permis d’établir le profil de résistance du VHC contre ce composé. Grâce à cette 
fine cartographie, il a été possible d’identifier un nouveau mécanisme d’inhibition de NS3/4A 
qui est indépendant de son activité protéase.  
 
En utilisant les données de notre groupe sur les interactions VHC-hôte, il a été possible 
de continuer la caractérisation fonctionnelle du composé UM42811 en étudiant son effet sur 
les interactions potentiellement bénéfiques à la persistance virale.  Pour ce faire, les protéines 
associées au transport nucléaire et mitochondriale qui sont des interactants de choix de 
NS3/4A ont été priorisées. Parmi ces facteurs de l’hôte, l’étude de karyopherin subunit beta 1 
(KPNB1) et de heat shock protein 60 (HSP60) a été priorisée. De façon intéressante, les 
expériences de co-immunoprécipitation ont démontré que UM42811 était capable de prévenir 
l’interaction KPNB1-NS3/4A ainsi que l’interaction HSP60-NS3/4A. De plus, les études 
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fonctionnelles et les analyses d’immunobuvardage de type western ont démontré que 
l’interaction KPNB1-NS3/4A avait des effets délétères sur l’induction des gènes stimulés par 
l’interféron (ISG). Finalement, il a été démontré que KPNB1 est possiblement clivé par 
NS3/4A suggérant la présence potentielle d’un mécanisme de subversion ou d’échappement.   
 
 En bref, cette étude démontre la puissance des stratégies impliquant les interactions 
protéine-protéine dans les cellules vivantes pour l’identification de nouveaux composés 
inhibiteurs, caractérise un nouveau mécanisme d’inhibition anti-VHC et révèle la possibilité 
d’un nouveau mécanisme d’évasion du système immunitaire. 
 
Mots-clés : virus de l’hépatite C, VHC, antiviraux à action directe, ADD, criblage à haut 
débit, BRET, interaction protéine-protéine, résistance 
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Abstract 
Hepatitis C virus (HCV) is an important causative agent for liver diseases and is 
responsible for a worldwide pandemic affecting roughly 180 million individuals worldwide. 
Late diagnosis following the progression to fibrosis and to cirrhosis, in nearly 16% of chronic 
infections, is attributed to the absence of symptoms in the first years of infection. 
 
By exploiting membrane protein-protein interactions (PPI), live cell assays using 
bioluminescence resonance energy transfer (BRET) technology have previously been 
optimized to complete a comprehensive hepatitis C virus (HCV) protein interaction network. 
Using the groundwork laid by this network study, a high-throughput assay (HTS) cell-based 
assay was implemented to identify novel inhibitory compounds targeting an unreported 
NS3/4A-NS3/4A interaction. Approximately 110,000 compounds from a small-molecule 
collection were screened to monitor modulation of NS3/4A homodimerization and were 
discriminated based on specificity and potency. UM42811 was identified as a potential 
NS3/4A-NS3/4A interaction activator and found to have a promising antiviral activity 
boasting an excellent therapeutic window. Combined deep sequencing and mutation mapping 
have yielded a resistance profile based on statistical and functional probability pointing 
towards a novel inhibitory mechanism targeting the HCV NS3/4A independent from protease 
activity inhibition.  
 
Data from an HCV to host protein interaction network generated by our group was 
used to analyze alternative effects of UM42811 on interactions which potentially benefit viral 
persistence. NS3/4A-specific host interactors were heavily associated with nuclear and 
mitochondrial transport based on Gene Ontology (GO). Among these specific interactors, 
karyopherin subunit beta 1 (KPNB1) and heat shock protein 60 (HSP60) were selected for 
further study. Interestingly, co-immunoprecipitation experiments revealed that UM42811 was 
able to prevent both KPNB1-NS3/4A and HSP60-NS3/4A interactions. Moreover, functional 
and western analysis revealed the KPNB1-NS3/4A interaction to have deleterious effects on 
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interferon stimulated gene (ISG) induction. Unexpectedly, analysis revealed a putative 
NS3/4A mediated cleavage of KPNB1.  
 
Overall, this study demonstrates the strength of cell-based PPI strategies in the 
identification of novel HCV antiviral compounds, characterizes a novel inhibitory mechanism 
for HCV and reveals a potentially novel viral immune evasion mechanism. 
 
Keywords : Hepatitis C virus, HCV, direct-acting antivirals, DAA, high-throughput 
screening, HTS, bioluminescence resonance energy transfer, BRET, protein-protein 
interaction, PPI, resistance 
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Introduction 
 
 
  
1. Global Significance 
 
1.1. Virus Discovery 
 
The historical background surrounding the discovery of Hepatitis Cvirus (HCV) is 
quite interesting and is undeniably important to fully appreciate the global significance of the 
virus. In the early 1960s, Hepatitis A virus (HAV) and Hepatitis B virus (HBV) were the only 
established causative agents of viral hepatitis though other viral agents such as 
cytomegalovirus and Epstein-Barr virus were known to cause liver damage as a generalized 
infection characteristic(1).  
 
Before the advent of specific serological assays, clinical and epidemiological features 
distinguished type A from type B hepatitis; while hepatitis A was characterized by an acute 
infection of short incubation period transmitted via the oral-fecal route, hepatitis B was 
defined by a blood-borne infection of long incubation period (2).  It was only after the 
development of specific antigen and antibody testing and the subsequent findings of patients 
with viral hepatitis lacking positive serologies for hepatitis A and B that, in the mid-70s, a 
Non-A Non-B hepatitis (NANBH) was described (1, 2). Though the identification of 
NANBH-specific antibodies did not occur until 1985 (3), standard HAV and HBV testing 
along with the use of elevated serum alanine aminotransferase (ALT) levels as a specific 
marker for hepatitis quickly linked patient onset of NANBH with contaminated blood 
transfusions (4, 5). 
 
In 1989, following the long-awaited full isolation of a complementary DNA (cDNA) 
clone derived from a NANBH genome along with the discovery of a positive-stranded RNA 
virus of 10 000 nucleotides, hepatitis C virus was, for the first time, used in place of NANBH 
(6). 
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1.2. Worlwide Prevalence 
 
Following the official discovery of HCV in 1989, the World Health Organization 
(WHO) released a report attributing over 90% of NANBH cases to the virus (7). It was also 
estimated, at the time, that approximately 100 million people worldwide were chronically 
infected (7). The global prevalence estimates have since increased, but have not changed 
significantly over recent years, partly due to the lack of new and more accurate data. As of 
late, assessments are still approximating a global prevalence of 235:10,000 or roughly 160 
million chronically infected individuals (8).  
 
Many cases of HCV infections go undiagnosed as acute infections are symptomatic in 
only an estimated 15-30% of cases (9) and as nearly a quarter of all acute infections are 
spontaneous cleared (10). Left untreated, chronically infected individuals are at risk of 
developing cirrhosis with an estimated probability of 16% after 20 years and that probability 
increases exponentially with prolonged infection (11). Similarly, hepatocellular carcinoma 
(HCC) develops in 1-3% of these cases 30 years post-infection (12). Looking at its 
contribution in annual deaths, in 2010, about half a million worldwide deaths were attributed 
to HCV infection representing, but not restricted to, 28% of all cirrhosis-related and 26% of all 
HCC-related deaths (13). 
 
While the global burden of HCV-associated advanced liver disease is useful to depict 
the gravity of the HCV pandemic, the actual trends relating to the evolution of chronic 
infection within given countries provide interesting insights towards predicting future problem 
areas. When considering age-specific prevalence data (14, 15), three broad patterns consistent 
with temporal patterns of HCV incidence, heavily related to iatrogenic exposure or injectable 
drug use, can be defined.   
 
The first pattern describes countries where HCV is endemic and where there is very 
little sign of decreasing prevalence. Egypt is one such example and is characterized by very 
high transmission rates of which a third is still attributed to improper medical tool sterilisation 
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and inadequate screening methods prior to blood transfusions (16). Over the 20 years leading 
to 2020, given its long incubation period, HCV-related mortality is predicted to increase at 
least 2.4 fold with more than 20 000 HCV-related predicted deaths in 2020 (17). 
 
The second pattern describes countries such as Japan and Italy where peak HCV 
incidence occurred several decades ago, often through iatrogenic exposure, and where current 
HCV prevalence and incidence are low due to proper screening and disease control. In these 
countries, HCV-related mortality is likely already on the decline (18, 19).  
 
The last of the three patterns describes countries that generally have low HCV 
prevalence but have an increased prevalence in middle age groups likely due to later trends of 
injection drug use (20). In these countries, including USA, Australia and several countries of 
Western Europe, trends of HCV-related advanced liver disease are expected to follow those 
seen in Japan except with a considerable lag given that HCV infections only peaked at the turn 
of the millennia (20, 21). Because the development of HCV-associated liver complications 
occurs a number of decades after initial infection, in the USA, annual liver-related deaths are 
projected to increase until 2030 (21).  
 
 Over 20 years have passed since the discovery of HCV, it is clear that HCV is of global 
importance, establishing itself as a widespread global health issue, and reinforces the need of 
proper interventions for its prevention and control.  
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1.3. Genetic Variance, Genotypic Distribution and Origins 
 
HCV like many RNA viruses is extremely prone to mutations; human hosts are 
capable of producing up to 10
12
 virions a day (22) with a calculated 3.5 × 10
 -5
 mutations per 
replication cycle (23). While bad news for the host, high genetic diversity is generally 
important for the evolution of the virus as it potentially confers immune escape, vaccine 
evasion, drug resistance and new host adaptability mechanisms (23).  
 
HCV is made up of seven phylogenetic clades or genotypes, each with their own 
subtypes. The total sequence divergence within these subcategories is approximated at ~30% 
and at ~20% respectively (24). Moreover, natural mutations occurring within a chronically 
infected individual produce a closely related but heterogeneous population of HCV isolates 
referred to as quasispecies. Though genotype switching is uncommon, very rarely and in some 
special cases it has been observed (25, 26).  Though no definitive link between genotype and 
pathogenicity has been made (27), identifying the genotype of an infection is relevant for 
treatment regimen in addition to providing important insight for HCV epidemiology.  
 
Because genotyping is based on the sequence divergence within highly conserved 
subgenomic regions, namely E1, core, NS5B and 5’UTR (28), determining whether the 
mutability of HCV alone is enough to account for the existence of different genotypes and 
subtypes is, to certain extent, dependent on the origins of the virus. Although the concepts of 
non-human primate and equine origins have been explored (29) and although multiple cross-
species transmission events could explain important sequence discrepancies between 
genotypes, the true origins of the virus have yet to be elucidated. Though the differentiation of 
genotypes does not necessarily resolve the true origin of HCV, it certainly provides some 
insight into the circulation and the recent spread of HCV on the basis of distinctive genotypic 
features: affected risk groups and geographical distribution (29).  
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Genotype 1, 2 and 3 are relatively widespread worldwide. However, among the three, 
genotype 1 has the greatest geographical distribution as it affects much of the developed 
western world including most of North America (30), Northern and Western Europe (31). 
Genotypes 4, 5 and 6 have more restricted geographical distributions, but do not seem to 
display any less genetic diversity than genotypes 1 to 3. Genotype 4 is found predominantly in 
the Middle East (32). Genotype 5 is almost exclusively found in South Africa (33). Genotype 
6 is common to Southeast Asia (34). Not much is known about genotype 7, but it is believed to 
originate from Central Africa (35).  
 
Because transmission from mother to child or sexual contact is largely inefficient (15), 
the widespread use of blood transfusion and other parenterally delivered treatments, none of 
which were common risk factors prior to the Second World War, is perhaps not coincidently 
in concordance with genotype 1b, 2a and 2b being mostly prevalent in the older population of 
Europe and Asia (29). In parts of Europe, increases in genotype 3a (36, 37), which typically 
infects injection drug users (IDUs) (29), may reflect the reduced contribution of iatrogenic 
transmission and the increased transmission through injection drug use. 
 
Despite similar intragenotypic diversity, discrepancies within genotype-specific 
distribution patterns has been suggested to be the combined result of recent epidemic spread 
into new risk groups overlaid on top of a much older circulation of HCV(29). Globally 
prevalent infections such as 1a, 1b, and 3a may fortuitously be the most successful variants to 
enter previously unexposed susceptible individuals through parenteral transmission. 
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Figure 1. Worldwide estimated prevalence of HCV and genotype distribution  
Visual representation of estimated region-specific prevalence of HCV infection and 
region-specific distribution of HCV genotypes. Countries of the middle east like Egypt have 
the highest prevalence of HCV infection and are predominantly characterized by genotype 4 
infections. While genotype 1 has the largest worldwide distribution, genotypes 4, 5, and 6 are 
for the most part region specific affecting Southeast Asia, South Africa, and Egyptian middle 
east respectively. (permission from Hajarizadeh B, et al., Nature Reviews Gastroenterology & 
Hepatology., 2013. Copyright Nature Publishing Group 2013) (38) 
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2. HCV Lifecycle 
 
2.1. Viral Entry 
 
During primary infection, HCV particles are transported through the blood stream until 
they reach the basolateral surfaces of hepatocytes. There, the virus becomes concentrated by 
interacting with host factors with low affinity prior to interacting with subsequent essential 
entry factors. This initial low-affinity attachment involves interaction between host factors 
such as the heparan sulfate proteoglycans syndecan-1 and syndecan-4 and low-density 
lipoprotein receptor (LDLR) and components of the viral particles such as apolipoprotein E 
(apoE) and the envelope glycoproteins E1 and E2 (39-41).  
 
The steps following this initial attachment phase are partially understood and involve a 
number of proposed host factors of which 4 are generally accepted: scavenger receptor B1 
(SRB1) (42), tetraspanin CD81 (43), and tight junction proteins claudin-1 (CLDN1) (44) and 
occludin (OCLN) (45). Other factors include the cholesterol transporter Niemann-Pick C1-like 
1(NPC1L1) (46), transferrin receptor 1 (TfR1) (47), and ephrin receptor A2 (EphA2) (48). 
Interestingly, SRB1 seems to play an intermediary role between the attachment and post-
attachment phases of viral entry. Though SRB1 has demonstrated primary interaction with 
virion apolipoproteins, its lipid transfer activity appears to be the determining factor for 
productive viral entry (49, 50).  
 
CD81, probably the most recognized among entry factors, once bound with E2 prime 
low pH-dependent fusion of viral endocytosis (51). Co-receptor complex formation between 
CD81 and CLDN1, which occurs more so at the basolateral membrane than at tight junctions, 
appears to be required however (52) and precedes its co-internalization with HCV particles 
during clathrin-dependent endocytosis. The discrepancy found within the localizations of these 
co-receptor complexes possibly implicates epidermal growth factor receptor (EGFR). EGFR, 
through downstream signaling pathways, promotes the lateral diffusion of CD81 and thus 
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facilitates the formation of the CD81-CLDN1 complex (53). While the precise role of OCLN 
in the HCV life cycle has yet to be clearly defined, cell-to-cell spread has been reported as the 
principle mode of HCV transmission (54). Following fusion, the HCV genome is released into 
the cytosol where translation and replication can begin. 
 
2.2. Genome Translation and Replication 
 
Original analyses of the amino acid sequences extrapolated from the nucleotide 
sequences of HCV initially revealed a gene organization similar to those of flaviviruses. HCV 
was later assigned to a new genus, Hepacivirus, within the Flaviviridae family and is therefore 
a Baltimore class IV single stranded RNA virus of positive polarity (+ssRNA).  
 
The HCV genome contains a single open reading frame (ORF) and rather than a 5’cap 
or a 3’ poly A tail has highly structured RNA elements within its 5′ and 3′ non-translated 
regions (NTRs) to protect itself and assist with translation initiation (55). The 5′NTR contains 
an internal ribosomal entry site (IRES) to initiate translation (56) in addition to a microRNA 
122 (miR-122) binding site (57). Contribution of miR-122, a liver-specific microRNA, has 
been shown to be indispensable to HCV replication by slowing exonuclease Xrn1 mediated 
degradation of HCV RNA (58) through its association with Argonaute 2 at the 5’end (59). 
Conversely, though no definitive consensus has been reached, the 3’ untranslated region 
(UTR) has been shown to have stem loop structures which, in conjunction with an upstream 
5BSL3.2 stem loop within the NS5B coding region, are equally as important for HCV 
replication and translation (60, 61). 
 
 HCV genomic RNA is translated into a single polyprotein and is subsequently 
processed by viral and host encoded proteases into 10 mature proteins: core, E1, E2, p7, NS2, 
NS3, NS4A, NS4B, NS5A, and NS5B (62). Host signal peptidases and signal peptide 
peptidases process the structural proteins of HCV by mediating the cleavage at the core/E1, 
E1/E2, E2/p7 and p7/NS2 junctions. Moreover, the NS2 cysteine protease, whose activity is 
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enhanced by the N-terminus of NS3, mediates the cleavage of the NS2/NS3 junction freeing 
the NS3/4A serine protease. NS3/4A processes most of the non-structural (NS) proteins by 
mediating the cleavage of the NS4A/4B, NS4B/5A, and NS5A/5B junctions while also 
cleaving itself and other host factors (see chapter 2.4).  
 
 Once the polyprotein is fully processed, HCV induces massive rearrangements of 
intracellular membranes creating a sophisticated micro-environment called the “membranous 
web” to replicate its genome (55). This membranous web is particular to HCV and has been 
shown to be predominantly characterized by double-membrane vesicles (DMV) (63). While 
NS3/4A, NS4B, NS5A or NS5B alone can induce some membrane remodeling, the 
cooperative effect of each is required for a fully functional ultrastructure. There are, however, 
particular structural contributions which are differentially attributed to these NS proteins. 
NS4B’s oligomerization capacity has been suggested to be responsible for the scaffolding of 
membranous vesicles (64) while NS5A has been shown to be uniquely responsible for the 
induction of DMVs (65).  
 
To follow suit, nascent genomic RNA is translated to produce either new viral 
polyproteins or RNA intermediates necessary for replication of genomic RNA. While RNA 
synthesis is the primary responsibility of the RNA-dependent RNA polymerase (RdRp) NS5B, 
lipid droplets (LD), triacylglycerides and cholesteryl esters deposits encapsulated by a 
phospholipid monolayer, are thought to play a key role in the coordination of viral RNA 
synthesis and the production of infectious particles (66).  
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2.3. Assembly and Release 
 
The final stages of the HCV lifecycle require the careful spatiotemporal coordination 
of viral genomic RNA and structural proteins for the maturation of viral particles (67). A 
peculiarity of HCV morphogenesis is its complex interconnection with lipid metabolism. As a 
consequence, a plethora of host factors have arose in literature reporting varying degrees of 
contribution to HCV morphogenesis. For instance, host factors involved in very low-density 
lipoprotein (VLDL) synthesis pathways such as microsomal triglyceride transfer protein 
(MTP) (68), acyl-CoA synthetase 3 (ACSL3) (69) and hepatocyte nuclear factor 4α (HNF4α) 
(70) have been shown to play a role in the process. 
 
 LDs are established key players within viral assembly. While they are normally 
distributed throughout the cytoplasm in uninfected cells, HCV infection induces their 
perinuclear accumulation (71) and consequently their proximity to replication machinery. The 
interaction between HCV core protein, which forms the nucleocapsid, and LDs is essential for 
the recruitment of viral factors implicated in assembly (66) as confirmed by mutational studies 
in which this interaction is abrogated (72, 73). Cellular factors have also been shown to 
influence this core-LD association. For instance, host factors like diacylglycerol 
acyltransferase-1 (DGAT1) (74), an enzyme involved in lipid synthesis, and MAPK-regulated 
cytosolic phospholipase A2 (PLA2G4) (75), an enzyme involved in lipolysis, are reported to 
be involved in core trafficking to LDs. IκB kinase-α (IKK-α) has also been shown to influence 
this interaction through downstream lipogenic gene induction pathways (76). 
 
 While trafficking of core to LDs is vital for viral assembly, the coordination of other 
viral factors to assembly sites near LDs is also necessary (66). This includes HCV 
glycoproteins E1 and E2 that form a non-covalent heterodimer otherwise retained in the ER 
(77). NS2’s interaction with these factors and viroporin p7 was reported to assist in this matter 
(78, 79).  
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Other NS proteins have also been shown to contribute to the assembly phase. Among 
them, NS5A emerges as a central player. While its interaction with LDs has been shown to be 
required for assembly (66), its phosphorylation at a specific serine residue by casein kinase II 
was shown to prompt the transition between replication and assembly (80). Similarly, 
NS3/4A, through its interaction with Y-box-binding protein 1 (YB-1), has been shown to 
influence the equilibrium between RNA replication and the production of infectious particles 
(81). 
 
 Following assembly, HCV particles are released through the secretory pathway (82) 
where the endosomal-sorting complex required for transport (ESCRT) pathway, exploited by 
many enveloped viruses (83) has also been proposed to play a role. It has been suggested that 
neutralization of acidic compartments by HCV p7 during these later stages protects newly 
formed particles (84).  
 
2.4. Innate Response and Immune Evasion 
 
The coevolution of hosts and viruses has granted the cell many mechanisms to 
recognize and defend against viral pathogens. In response to HCV infection in particular, there 
is a strong induction of type I IFNs and of IFN stimulated genes (ISGs). This response begins 
with the detection of foreign invaders through pattern recognition receptors (PRRs) (85). In 
the case of HCV infection, these specifically involve RIG-I and Toll-like receptors (TLR)-1, -
3, and -7. Following recognition, signal transduction continues through adaptor proteins TIR-
domain-containing adapter-inducing interferon-β (TRIF), myeloid Differentiation Primary 
Response 88 (MYD88) and mitochondrial antiviral-signaling protein (MAVS). These effectors 
then activate the transcription factors IRF3, IRF7 and NF-κB and consequently lead to their 
nuclear translocation. This allows the induction and transcription of type I and type III IFNs, 
whose secretion will alert neighboring cells. Although both type I and type III IFNs share a 
number of biological properties, they remain relatively distinct. For instance, while 
peroxisomal MAVS can induce type III IFNs (86), it is unable to induce type I IFNs (87). 
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Secreted IFNs are then detected by IFN receptor complexes (IFNAR1/IFNAR2 complex for 
type I IFNs and IFN-λR1/IL-10R2 complex for type III IFNs (88)) with IFN-λ receptors being 
more restricted to epithelial cells than the ubiquitously expressed IFN-α/β receptors (89). 
Signal transduction from either complex continues through the JAK/STAT pathway 
demonstrating differences in kinetics (90) and ultimately culminating in the induction and 
transcription of ISGs. The transcription of inflammatory cytokines, PRRs and effector proteins 
keeps cells on high alert and maintains their antiviral state (85).   
 
In response, HCV has developed many strategies to deal with host defenses and to 
allow it to establish a persistent infection. Among the better characterized mechanisms is the 
protease activity of the NS3/4A protein responsible for the cleavage of MAVS (91) and TRIF 
(92). As a result, the RIG-I and TLR3 mediated early IFN response are inhibited. While 
NS3/4A predominantly affects the early IFN response, core has been shown to play a role in 
hindering the late response by inhibiting the JAK/STAT pathway through its interaction with 
STAT1 (93) and through the induction of suppressor cytokines SOCS1 and SOCS3 (94, 95). 
Additionally, HCV glycoprotein E2 (96) and NS5A (97) have been shown to inhibit IFN 
signalling through their interaction with ISG.protein kinase R (PKR) Beyond its interaction 
with PKR, NS5A has been shown to interact with another ISG 2’5’ oligoadenylate synthethase 
(OAS) (98) achieving the same effect. Despite these evasion mechanisms, the activation of the 
IFN response remains detectable in patients. A rapid IFN response preceding the effect of viral 
evasion mechanisms and the lack of infection in all hepatocytes has been suggested to be 
responsible for these observations (99).  
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3. Treatment Evolution 
 
HCV is a prime example that accurately represents the collective contribution of 
rigorous research to the evolution of treatment and prospective eradication of disease. From 
early type I IFN-based therapies riddled with side-effects which hinder treatment adherence to 
modern combination therapies which approach the pan-genotypic, treatment of HCV infection 
has a long and complex history.  For HCV treatments, a therapy is considered effective when 
sustained virologic response (SVR) is achieved. SVR is described as the state where the virus 
remains undetectable following a period, typically 24 weeks, after treatment is concluded. 
The Schering-Plough Corporation was the first to introduce an HCV treatment with 
their IFNα-2b recombinant, Intron A, being approved by the FDA in 1991 (100). Roche 
Pharmaceuticals would follow suit with their IFNα-2a treatment, Roferon A, being approved 
by the FDA in 1996. The IFN mono-therapy, however, had a poor therapeutic response with 
less than 20% of treated individuals achieving SVR (101). Merck, who would later acquire the 
Schering-Plough Corporation, brought on much needed improvements with the introduction of 
pegylated-IFN (PEG-IFN) and the addition of ribavirin (RBV) to treatment therapy. RBV was 
Originally discovered in 1972 as a guanosine analogue with broad spectrum activity against a 
number of RNA and DNA viruses (102), RBV was commercialized for hepatitis C treatment 
under the name Rebetol in 1998. On the other hand, the conjugation of IFN with polyethylene 
glycol allowed protection from proteolytic breakdown and thus increased its biological half-
life alleviating difficulties associated with treatment adherence (103).  In 2001, these 
milestones would establish the standard of care (SOC) for the next decade. Because genotype 
1 patients were classically considered the most difficult to treat, therapeutic efficacy was still 
suboptimal allowing but 40% of infected individuals to attain SVR (104). In light of this, 
attempts continued to introduce better therapeutic regimens. 
 With the growing body of information surrounding the HCV life cycle and the role of 
individual viral proteins, the next revolution in treatment came in the form of direct-acting 
antivirals (DAAs). The first evidence of the potential of these novel anti-HCV agents 
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specifically designed against essential viral enzymes was with the discovery of BILN 2061. 
Even though its clinical development was interrupted due to some evidence of cardiotoxicity 
at high doses in rhesus macaques, the efficacy of BILN 2061 in humans established the first 
proof-of-concept for an NS3 protease inhibitor (105). With the momentum gained from these 
findings, in 2011, the first generation of DAAs boceprevir (Merck) and telaprevir (Vertex) 
were finally approved, introduced and added to the previous PEG-IFN/RBV regimen. These 
new triple therapies led to higher SVR rates, but still had the adverse effects of IFN-based 
treatment (106). Triple therapy with boceprevir or telaprevir quickly fell out of favor with the 
introduction of new wave DAAs. For instance, sofosbuvir (Gilead) which was approved by the 
FDA at the end of 2013 in combination with PEG-IFN/RBV raised the standards by achieving 
SVR rates approaching 90% (107).  
 
Competing groups gradually developed and introduced a plethora of increasingly 
potent DAAs using different drug design strategies (detailed in chapter 3.1) often inspired by 
each other. Eventually culminating in late 2014, a new generation of all oral IFN-free 
combination therapies became available. Boasting excellent SVR rates, high genetic barrier to 
resistance as a result of the multi-pronged approach all without the undesirable IFN associated 
side effects, combination DAA therapies (detailed in chapter 3.3) mark the success of years of 
research from discovery of a virus to near optimal treatment design. 
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3.1. Direct Acting Antiviral (DAA) – Design Strategies 
 
In principle, every step of the HCV replication cycle is a potential target for drug 
design. However, early technical limitations such as a lack of a robust replication system 
(discussed in chapter 4.2) and of structural information for HCV historically made designing 
DAAs difficult. Coincidentally, fortunate discoveries coupled with systematic research 
chronologically lead NS3/4A protease, NS5B polymerase, and NS5A phosphoprotein to 
become the primary and most successful targets for HCV-specific DAAs though other viral 
targets such as NS4B (108) and p7 (109) have been explored. 
 
3.1.1. NS3/4A Serine Protease 
 
The NS3/4A serine protease is a heterodimeric enzyme that belongs structurally to the 
trypsin superfamily and is comprised of the N-terminal domain of the NS3 as well as the 
NS4A protein. It is unique, however, within its classification, for its requirement of a viral 
cofactor and of a structural zinc atom (110). 
 
While the N-terminal domain of NS3 is responsible for the protease function, the C-
terminal two-thirds of NS3 function as an RNA helicase belonging to the DExH family (111). 
Though its exact function within the HCV lifecycle is unclear, based on functional homology, 
it may be involved in RNA folding/remodeling (112), polymerase processivity (113), and/or 
genome encapsidation (114). Whether the helicase activity functions as a monomer or 
oligomer and whether either form is more functionally fit is debatable though some evidence 
indicates that which form NS3 takes is dependent on relative concentrations of enzyme to 
substrate (115).The NS4A protease cofactor consists only of 54 residues making it a relatively 
small protein. The N-terminal hydrophobic region, predicted to form a transmembrane α-helix, 
is involved in anchoring the heterodimeric complex to the membrane while amino acids 21-34 
are directly implicated in the interaction with NS3 and are absolutely required (116). Crystal 
structures of NS3 with and without cofactor revealed that NS4A optimizes the orientation of 
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the catalytic triad residues and thereby stabilizes the protease domain of NS3 and increases 
enzymatic activity (117). 
 
The main functional purpose of NS3/4A is the cleavage of the viral polyprotein at the 
junctions between NS3/NS4A, NS4A/NS4B, NS4B/NS5A and NS5A/NS5B. The liberated 
viral proteins are a product of trans-cleavage events, while NS3 and NS4A result from an 
intramolecular cis-cleavage. These junctions possess a consensus sequence of Asp/Glu-(Xaa)4-
Cys/Thr ↓ Ser/Ala-(Xaa)2-Leu/Trp/Tyr (118). This consensus sequence agreed with later 
studies that characterized the requirement of decamer peptide substrates spanning P6-P4’ 
(Schechter & Berger nomenclature (119)) and defined preferences for an acidic residue in P6, 
cysteine in P1, serine or alanine in P1’, and a hydrophobic residue in P4’ (120-122). The 
NS3/4Aprotease lacks several surface loops at the substrate binding cleft found in other serine 
proteases (110). As a result, the solvent-exposed and relatively featureless substrate binding 
site posed a great challenge in the design of small molecule inhibitors and selection of non-
peptidic candidates from compound collections. 
 
3.1.1.1. NS3/4A Protease Inhibitors (-previr) 
 
Based on the enzymatic features derived mainly from X-Ray crystallography studies, 
three distinct strategies for developing inhibitors against the NS3/4A serine protease were 
contemplated. These strategies consisted of interfering with either the NS3/NS4A interaction 
or the binding of zinc, and preventing substrate binding to the active site. The first two 
strategies are still, however, considered extremely difficult (123) and drug candidates of this 
category are virtually nonexistent. For instance, nonpeptidic small molecule inhibitors such as 
certain benzimidazole-based compounds inhibit the enzyme by exploiting its interaction with 
zinc (124). Though noncompetitive allosteric inhibitors, emerging mainly from random 
screening, could have potential within combination therapies, due to the nature of the method 
by which they are identified, the necessity of extensive safety assessments makes their 
development problematic.  
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With the insights gained from the design of human immunodeficiency virus (HIV) 
protease inhibitors, and with the large body of structural data surrounding the enzyme and its 
substrate, active site inhibitors were the first to be successfully developed and continue to be 
considered the most promising and widely used approach. Though, initially, the absence of a 
well-defined substrate binding site had raised concerns for the design of low molecular weight 
inhibitors, early breakthroughs lead to the emergence of two main mechanistic classes of 
active site-based inhibitors, namely covalent and product analogue inhibitors(125). 
 
3.1.1.1.1. Covalent Inhibitors 
 
Often referred to as transition state analogues or serine-trap inhibitors, covalent 
NS3/4A inhibitors are product-based inhibitors conceived through the replacement of the 
scissile amide bond with an electrophilic warhead. When the catalytic serine (S139) of the 
protease attacks the electrophilic warhead, a chemical formation which mimics and locks the 
transition state of peptide bond cleavage is generated. Despite classic electrophile-based 
covalent inhibitors functioning via an irreversible mechanism and despite speculations of 
clinical restrictions due to the possibility of unspecific irreversible binding (126), NS3/4A 
protease inhibitors of this mechanistic class were the first to be approved by the FDA. 
Notably, of the various electrophilic warhead alternatives, the early success of both boceprevir 
(Merck) and telaprevir (Vertex)  is owed in part to the unusual mechanism by which linear α-
ketoamide derivative inhibitors allow reversible binding to the catalytic site of the viral 
enzyme(127). 
 
3.1.1.1.2. Product Analogues 
 
This mechanistic class is comprised of competitive, reversible, mostly macrocyclic, 
noncovalent inhibitors whose drug design efforts were initiated by early findings regarding the 
susceptibility of the NS3/4A protease to feedback inhibition (128, 129). 
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With structural studies characterizing substrate specificity, and the importance of the 
P1 residue (see chapter 3.1.1.) to the potency and specificity of serine protease ligands (130), 
the major challenge for the development of N-terminal product-like inhibitors was designing 
proper chemically stable replacements for the P1 sulfhydryl group. Amino acid substitutes 
whether those with small hydrophobic side chains or those with larger side chains, both lead to 
a loss of potency either due to reduced contact surface area or steric incompatibility (128).  
Eventually, the continuing research efforts culminated in the successful replacement of the 
unstable P1 residue with aminocyclopropane carboxylic acid (ACCA) derivatives (131, 132). 
The addition of a macrocyclic ring that connected the side chain of the P1 and the P3 residues 
and the stepwise optimization which followed proved to be useful in improving affinity and 
specificity, while preserving bioavailability characteristics of small molecules (133). 
Ultimately this resulted in the discovery of the compound BILN 2061 or ciluprevir (105). 
Macrocyclization was truly a breakthrough in NS3/4A protease inhibitor design, as many 
subsequent drug candidates, though varying in C-terminal moieties for improved 
pharmacokinetics, retain essentially the same core P1 ACCA and accompanying structures. 
Simeprevir (Janssen), paritaprevir (AbbVie), and grazoprevir (Merck) are notable examples 
for this mechanistic class of protease inhibitors and are showcased within upcoming 
combination therapies. 
 
 Rather than focus on the N-terminal product, certain groups explored the C-terminal 
side of the scissile bond for competitive inhibition. These groups observed that P1’ 
substitutions with proline, tetrahydroisoquinoline-3-carboxylic acid (TIC) or pipecolinic acid 
(PIP) generated noncleavable substrate analogues (120). Despite boasting equally high 
potency and selectivity, development of clinical candidates was never fully engaged due to 
their large molecular weights and hence their poor pharmacokinetics.  
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3.1.2. NS5B RNA-Dependent RNA Polymerase 
 
As the RNA-dependent RNA polymerase of a positive stranded RNA virus, NS5B is 
required for the synthesis of negative stranded RNA intermediate and subsequently that of 
positive polarity RNA genomes. Early in vitro studies using purified NS5B had already 
described the enzymatic activity of NS5B as being indiscriminate, but primer-dependent 
(134). Further progress in regards to HCV NS5B was hindered by difficulties associated to its 
poor solubility, a consequence of being a component of a membrane-bound complex (135). 
Interestingly, while the full-length enzyme displayed rather poor catalytic activity (136) the 
removal of the dispensable C-terminal hydrophobic tail, consisting of 21 residues and 
responsible for the ER membrane targeting of NS5B (137), resulted in enhanced enzymatic 
activity (138) and most importantly enhanced solubility which greatly facilitated the 
determination of 3D structures.  
 
 
The unliganded crystal structure of NS5B, reported by several groups (139-141), had 
revealed unique structural features which could be manipulated in later drug design. While 
NS5B acquired the overall classic “right hand” shape, which included fingers, palm and thumb 
subdomains, it differed from the majority of cellular and viral polymerases which adopted a 
“half-open right hand” architecture. Due to the presence of two extended loops that span 
finger and thumb domains near the active site, NS5B adopted a more compact shape. The 
presence of a unique β-hairpin in the thumb subdomain which protrudes into the active site is 
another structural feature particular to NS5B. This may allow greater discrimination for 
template binding in a model which has previously been characterized as rather unspecific.  
 
While in vitro evidence supports a highly processive “copy back” mechanism, in 
which 3’-terminal-OH group of the template is used as a primer for polymerization (134), it is 
generally agreed that NS5B proceeds through de novo initiation since the alternative would 
lead to an eventual loss of terminal sequences that are indispensible for proper HCV 
replication (142).  
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3.1.2.1. NS5B Polymerase Inhibitors (-buvir) 
 
Due to the nature of viral replication and absence of RNA-dependent RNA 
polymerases in uninfected cells, targeting viral polymerases is invariably a straightforward 
choice in a drug design strategy and is unsurprisingly the rationale behind the majority of early 
approved antiviral drugs (143). For HCV, though an alternative mechanistic approach has 
been explored (144), polymerase inhibitors fall into two primary categories: 
nucleoside/nucleotide inhibitors (NI) and non-nucleoside/nucleotide inhibitors (NNI).  
 
The NS5B polymerase has multiple binding sites that can be targeted for inhibition 
among which the catalytic site is the most phylogenetically conserved (145). Because NIs 
induce premature elongation termination by acting as substrate analogues that bind 
competitively to the active site of the enzyme, NIs boast a high genetic barrier with only the 
S282T mutation being reported to confer resistance (145, 146). Sofosbuvir (Gilead), a 
phosphoramidate prodrug that becomes an active uridine nucleotide analogue after 
triphosphorylation, is an example of a NI of current interest.  
 
NNIs, however, can bind 4 different allosteric binding sites, located within the 
canonical thumb and palm domains (147, 148), and distort the precise geometry of the active 
site to significantly impair enzymatic function. Because these allosteric sites are not as 
conserved as the catalytic site, NNIs are more susceptible to resistance mutations. The thumb 
domain contains two binding pockets, the upper thumb (thumb I) and lower thumb (thumb II) 
which are characterized by distinct non overlapping resistance patterns (149). On the other 
hand, the palm domain contains partially overlapping palm I and II sites that also have an 
overlap in their resistance profiles (149). Though the design of these inhibitors is not quite as 
structured as that of NS3/4A protease inhibitors, palm I site inhibitors do have a recurrent 
structural benzothiadiazine-containing theme (149). Dasabuvir (AbbVie), an aryl 
dihydrouracil derivative, is an example of a palm I site directed NNI currently used in 
combination therapies.  
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3.1.3. NS5A Phosphoprotein 
 
NS5A is a zinc-binding phosphoprotein spanning 447 amino acids (150) that is 
described to be phosphorylated at several different regions by distinct kinases and, as a 
consequence (151-153), exists in two forms designated p56 and p58 based on electrophoretic 
mobility. Though functional differences between its forms have yet to be elucidated, essential 
host factor and NS5A interactant lipid kinase phosphatidylinositol 4-kinase III alpha 
(PI4KIIIα) has been shown regulate its phosphorylation (154). 
 
Structurally, the amino-terminus of NS5A includes an amphipathic α-helix, which is 
responsible for anchoring to the ER and ER-derived membranes such as lipid droplets (LDs) 
(155).This amphiphathic helix, comprised of the first 31 residues of NS5A, is also the only 
structural feature conserved in all HCV genotypes (156). NS5A can be divided into three 
distinct domains which are separated by linker regions (150). While domain I (D-I) residues 
were confirmed by biochemical assays to be involved in NS5A dimerization and RNA binding 
(157), domains II (D-II) and III (D-III) are thought to be responsible for NS5A’s large network 
of host interactants by fault of their intrinsically disordered and hence flexible nature (158, 
159).  
 
NS5A’s interaction with PI4KIIIα has been identified as having a central role in HCV 
replication as it induces the accumulation of phosphatidylinositol-4-phosphate (PI4P) within 
the membranous web and without which dramatic changes in ultrastructural morphology occur 
(160). Cyclophilin A through its contribution to de novo formation of double-membrane 
vesicles (DMV) (65) was also demonstrated to be a key host interactant essential for optimal 
HCV replication and has its own dedicated class of inhibitors (details in chapter 3.2.2.). ADP 
Ribosylation Factor GTPase Activating Protein 1 (ARFGAP1) (161), a GTPase-activating 
protein, and vesicle-associated membrane protein-associated protein A (VAP-A) and VAP-B 
(162) have also been shown to interact with NS5A with varying contributions to HCV 
replication.  
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Despite intrinsically lacking in enzymatic activity (163), NS5A is indispensible to 
HCV replication and its promiscuous ability to interact with numerous host factors is likely the 
source of its relevance.  
 
3.1.3.1. NS5A Inhibitors (-asvir) 
 
Classically, it was thought that NS5A was undruggable given the lack of characterized 
enzymatic activity (163). However, high throughput screening (HTS) using cell-based HCV 
replication systems serendipitously allowed the discovery of an early monomeric candidate 
which after subsequent chemical optimizations eventually led to dimeric daclatasvir (Bristol-
Myers Squibb) (164-166). The same study noted rapid emergence of key resistance mutations 
within the NS5A coding region and confirmed the inhibitor’s target. A subsequent study 
determined that previously identified Y93H and L31V amino acid substitutions within NS5A 
to roughly confer a 25 fold increase in resistance to daclatasvir individually, but a 15 000 fold 
increase when combined (167). These findings were also related to emerging resistance 
mutations in clinical settings further suggesting a specific drug binding site. 
   
Prior to the dimeric design of NS5A inhibitors, were a number of monomeric 
molecules which varied greatly in chemical scaffolds (166). Though emerging treatment-
induced mutations were also mapped at the homodimer interface in the crystal structure of 
NS5A, these inhibitors were not as effective as their eventual successor becoming optimal 
within the nanomolar range rather than the picomolar range (166).With the encouraging 
clinical results from daclatasvir, NS5A inhibitor design trends shifted towards utilizing a 
dimeric pharmacophore, featuring a conjugated bis-biaryl core terminated by peptidic caps 
(166). The current trend in NS5A inhibitor designs utilizes a dimeric pharmacophore, 
featuring a linear conjugated bis-biaryl core terminated by peptidic caps (166). While peptidic 
caps are relatively conserved among various drug candidates, the chemical composition of 
core linkers varies widely with a tendency to remain within range of 15-18 Å (166). There is 
however a preference for imidazole-proline coupling for the junction between the core and 
caps and a preference for conjugated aryl groups to bridge the midsection of the cores (166).  
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 The exact mechanism by which inhibition is achieved remains elusive with no 
definitive consensus even on whether inhibitor binding is symmetrical or asymmetrical within 
the NS5A homodimer (168). However, putative molecular mechanisms have been suggested 
to explain inhibition on HCV replication. It has proposed that this DAA class disrupts the 
function of new replication complexes rather than affecting preformed complexes while also 
causing the redistribution of NS5A to lipid droplets (LD) (169). Others have proposed 
mechanisms at the stage of assembly and release revolving around host factors such as 
PI4KIIIα and TIP47. These suggested mechanisms are unlikely exclusive and probably need 
to be combined to explain the biphasic clinical response to these DAAs (170).  
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3.2. Host-Directed HCV Inhibitors – Design Strategies 
 
Ingenuity is decidedly not lacking in HCV antiviral therapies. While DAAs are largely 
successful at inhibiting the virus, these strategies do not compare to the diversity found in 
host-directed HCV inhibitors or host-targeted agents (HTAs). 
 
3.2.1. RNA-Based Inhibitors 
  
The concept of utilizing RNA molecules as therapeutic agents was initially incited 
from the discovery that the entire HCV genome was translated into a single polyprotein via an 
internal ribosome entry site (IRES) (171). From there, the potential of trans-cleaving 
ribozymes (172) and antisense RNAs(173) as potential inhibitors of viral translation lead to 
the identification of ISIS 14803, a 20-base antisense oligonucleotide inhibitor (174), which 
was ultimately dropped during phase 1b clinical trials after generating inconclusive data. 
Eventually, the discovery of the liver-specific microRNA 122 (miR-122) and its possible role 
in HCV replication (57) reintroduced the potential of RNA-based treatments. With host miR-
122 as a target, another antisense oligonucleotide inhibitor was developed. Miravirsen 
(Roche), having shown moderate efficacy in treating chronically infected individuals (175), is 
currently undergoing phase II clinical trials as a monotherapy. 
 
3.2.2. Cyclophilin A Inhibitors 
 
Two classes of cyclophilin A inhibitors exist: classical cyclosporine and non-
immunosuppressive cyclosporine derivatives. The requirement of cyclophilin A for HCV 
replication was only truly demonstrated when the mechanistic prerequisite was shown to be its 
peptidyl-prolyl isomerase activity (176, 177) and when HCV NS5A was determined to be its 
viral ligand (178). As the cyclophilin A-NS5A interaction is conserved across genotypes, these 
host-targeted agents have the benefit of being pan-genotypic. 
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Though its initial discovery is not merited directly to anti-HCV efforts, these 
discoveries definitely emphasized the potential of cyclosporine in HCV therapeutics. For 
instance, cyclosporine A, a cyclic peptide of 11 amino acids, was originally sought after for its 
immunosuppressive activity which was achieved through a ternary complex formation 
between cyclosporine A-bound cyclophillin A and calcineurin (179). Its immunosuppressive 
ability was not favorable in the context of its anti-HCV ability, and so chemical modifications 
lead to the development non-immunosuppressive cyclosporine derivatives like alisporivir 
(Debiopharm), and N-methyl-4-isoleucine cyclosporine or NIM811 (Sandoz Pharmaceuticals) 
(180). Unlike its parent molecule, these derivatives while retaining its binary complex 
formation with cyclophilin A were unable to bind calcineurin. Normally, the N-methyl leucine 
at position 4 of cyclosporine occupies the calcineurin binding pocket however its substitution 
with N-ethyl valine or N-methyl-isoleucine allows respectively alisporivir (debiorivir) and 
NIM811 to be non-immunosuppressive (181, 182).  
Though some evidence attributed cyclosporine sensitivity to HCV NS2 (183), 
discrepancies in cyclosporine sensitivity between replicons lacking NS2 and full replicative 
systems which have NS2 were later described to be due to reduced replication competence 
because NS2-mediated polyprotein cleavage is the rate-limiting step in polyprotein processing 
(65). 
 
3.2.3. Entry Inhibitors 
 
Evidence for anti-HCV agents targeted at viral entry is varied and plentiful.  The 
continuing development of entry inhibitors has brought forth considerable insight towards the 
early stages of the viral cycle (see chapter 2.1. for details). Entry inhibitors can act at the 
specific stages of viral entry whether it is at initial attachment, post-binding entry or at the 
level of viral endocytosis/membrane fusion. Because this mostly involves some form of 
disruption or modification to the interaction between HCV envelope glycoproteins and host 
factors, as with other host-targeted agents, entry inhibitors tend to have a high genetic barrier 
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to resistance with largely HCV genotype-independent potency, but pose a greater risk of 
simultaneous cellular toxicity.  
Oriented towards the attachment and post-binding entry phases are: host-derived 
peptides like soluble low-density lipoprotein receptor (LDLR) (184), heparin-derived 
molecules (185),  recombinant human L-ficolin (186), and claudin-1 (CLDN1)-derived 
molecules (187); virus-derived peptides such as p7 ion channel-derived molecules (188); 
glycan-binding synthetic molecules such as lectin cyanovirin-N (189), and boronic acid-
modified lipid nanoparticles (190); structural mimic molecules like imidazole-based 
compounds (191); and natural compounds like epigallocatechin gallate (192) which is 
commonly found in green tea extracts. Though most candidates are in the in vitro stages of 
testing, a few have emerged in clinical trials. The savenger receptor B1 (SRB1) antagonist 
ITX 5061 (iTherX), an arylketoamide-based compound, is the most promising candidate of its 
class (193, 194) and is currently undergoing phase II of clinical trials. Because of its differing 
inhibitory mechanism, it also shows potential in combination with conventional DAAs (195).  
 
Lesser characterized entry inhibitors are: those that target the acidification mechanism 
of virion-cell membrane fusion like vacuolar ATPase inhibitors concanamycin A and 
bafilomycin A (196); and those that disturb the lipid balance required for membrane fusion 
such as phenothiazines (197) and indole derivatives (198).  
 
3.2.3. Immunomodulators 
 
Improving tolerability, efficacy and or pharmacokinetic properties of existing 
treatments and characterizing other immunomodulatory candidates are venues which have also 
been explored by certain research groups. More specifically affecting hepatocytes and 
consequently reducing haematological side effects, interferon analogues such as PEG-IFN-
lambda (199) and ribavirin analogues such as the taribavirin prodrug (200) have both 
undergone documented trials. More recent candidates which have been found to indirectly 
promote HCV elimination by bolstering the innate immune responses are nitazoxanide, a 
broad spectrum anti-parasitic that acts by improving interferon signalling, and toll-like-
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receptor (TLR)-7 agonists (201) which mediate endogenous interferon and cytokine release 
through the myd88 adaptor.  
3.3. Current Combination Therapies 
 
In December 2013, the approval of the polymerase inhibitor sofosbuvir (Gilead) in 
combination with PEG-IFN/RBV brought forth new optimism for IFN-free therapy. Boasting 
broad genotype coverage with high SVR rates ranging from 82% to 100% (202), the idea of 
dropping PEG-IFN in favor of DAA substitutes proved promising. Combined with protease 
inhibitor simeprevir (Janssen) or NS5A inhibitor daclatasvir (Bristol-Myers Squibb) with or 
without ribavirin, novel therapies which included sofosbuvir quickly demonstrated SVR rates 
well above previous standards covering beyond genotype 1 and proving efficacious in both 
naïve and previously treated patients (203, 204).  
 
From late 2014 and onwards, proprietary therapies using a combination of pre-
approved or novel re-optimized DAAs are likely to dominate the HCV therapeutic scene. 
Though other design strategies (see chapter 3.2.) may continue to improve with future 
iterations, they are unlikely to be competitive. Outside of cost considerations, current 
combination therapies have the clear advantage boasting excellent SVR rates across the board 
and conferring more confidence in their safety when compared to host-directed inhibitors.  
 
Currently, a number of combination therapies are available with more recent ones 
incorporating second-generation DAA iterations which are designed for broader genotype 
coverage (205). These all-oral IFN-free therapies achieve SVR rates approaching 100% within 
their designated genotypes, last typically between 12 to 24 weeks as opposed to the traditional 
24 to 48 weeks with IFN-based treatments, and demonstrate excellent treatment adherence and 
good tolerability profiles (206-214). In October 2014, the combination therapy Harvoni® 
(Gilead) was approved by the FDA for treatment of HCV genotype 1 and subsequently 
approved for genotypes 4, 5, and 6. It is comprised of first-generation NS5A inhibitor 
ledipasvir and first-generation nucleoside inhibitor sofosbuvir. In December 2014, Viekira 
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Pak™ (Holkira Pak™ in Canada, AbbVie) was approved by the FDA for the treatment of 
HCV genotype 1 infections including individuals with compensated cirrhosis. It is comprised 
of first-generation NS5A inhibitor ombitasvir, second-generation protease inhibitor 
paritaprevir coupled to pharmacological enhancer ritonavir and non-nucleoside inhibitor 
dasabuvir. In July 2015, AbbVie’s revised combination therapy Technivie™ was approved by 
the FDA for the treatment of HCV genotype 4, but is contraindicated for those with severe 
hepatic impairment. This package forgoes the inclusion of non-nucleoside inhibitor dasabuvir. 
In January 2016, Zepatier™ (Merck) was approved by the FDA for the treatment with or 
without ribavirin of HCV genotype 1 and 4. It is comprised of two second-generation 
molecules, namely protease inhibitor grazoprevir and NS5A inhibitor elbasvir. Finally, in June 
2016, the most recent combination therapy Epclusa® (Gilead) was approved by the FDA for 
treatment of chronic HCV infection genotypes 1 through 6 including comorbidities. This all-
oral IFN-free therapy is composed of second-generation NS5A inhibitor velpatasvir and first-
generation nucleoside inhibitor sofosbuvir. 
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Figure 2.  HCV lifecycle – Potential points of intervention 
Visual representation of the viral lifecycle of HCV. Numbered are the individual 
phases denoting: 1. Viral particle (where immunomodulators can be beneficial); 2. 
Entry/receptor interaction (detailed in chapter 2.1 and stage where entry inhibitors (chapter 
3.2.3) act); 3. Translation and polyprotein processing (detailed in chapter 2.2 and stage where 
NS3/4A and RNA-based inhibitors (chapters 3.1.1 and 3.2.1) act); 4. RNA replication 
(detailed in chapter 2.2 and stage where NS5B, NS5A, Cyclophilin A inhibitors (chapter 3.1.2, 
3.1.3 and 3.2.2) act); 5. Viral particle assembly (detailed in chapter 2.3 and stage where NS5A 
inhibitors (chapter 3.1.3) can act). (permission from Scheel T, and Rice C, Nature Medicine., 
2013. Copyright Nature Publishing Group 2013) (215) 
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4. Models for the Study of HCV 
4.1. Animal Models 
 
During the earlier days of HCV research, many factors involved in HCV infection were 
examined in chimpanzees. These include characteristics such as transmission, genetic drift, 
clinical outcome of infection, and the role of the immune response during infection (216, 217).  
Many human vaccine trials performed or initiated for HCV along with infectivity studies of 
HCV clones which lead to the development of cell culture systems are owed to studies done in 
chimpanzees (218). Despite the universally acknowledged contribution of this non-human 
primate model for the advancement of HCV research, prompted by ethical concerns, 
chimpanzee models have either been discontinued or been on the decline since 2011.  
 
While the first HCV infection studies in a mouse model were performed in 2001 (219), 
the decline of chimpanzee models in 2011 only deepened the interest in developing viable 
small animal models for HCV. Adaptations to this model were necessary however, given that, 
other than humans, persistent infection could only be established in chimpanzees (220). To 
this end, a number of strategies have been explored to humanize this small animal model. 
Because in vivo models are used to more closely mimic natural infection and the environment 
of the liver, strategies vary according to the particular host-viral protein interactions of 
interest. The first method attempts to gradually adapt HCV E1 and E2 to murine versions of 
entry factors such as CD81 and OCLN through prolonged exposure in culture. The second 
method uses transgenic expression of either HCV-specific or human-specific proteins in 
murine liver cells. FL-N/35 mice, the most well-known of transgenic mice, express the entire 
HCV polyprotein at close to physiological levels. They have been used to study hepatic 
steatosis, liver fibrosis and development of hepatocellular carcinoma. Alternatively, though its 
characteristics have yet to be properly defined due to the requirement of immune deficiency, 
expression of human CD81 and OCLN via an adenoviral vector has been attempted in mouse 
livers. A third method uses xenotransplantation of human hepatocytes to study HCV in mice. 
Immunodeficiency is required, however, to prevent rejection. This method also requires 
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murine liver injury as a means to provide a growth advantage to transplanted primary human 
liver cells (220). 
 
4.2. Cell Culture Based Systems 
 
Though animal models provide a more holistic and arguably accurate picture of HCV 
biology, many of the major discoveries regarding the HCV lifecycle, specific viral proteins 
and their enzymatic properties and the derivative identification of antiviral drugs are owed to 
cell culture based models of HCV.  
 
The first cell culture based system developed is the subgenomic replicon (221). The 
replicon system encodes viral proteins NS3 to NS5B and is therefore restricted to the study of 
the replicative portion of the HCV lifecycle. In this system, the IRES of HCV drives the 
expression of neomycin phosphotransferase which provides resistance to the G418 antibiotic 
and serves a selection marker. Conversely, the characteristically more efficient IRES taken 
from Encephalomyocarditis virus (EMCV) is used to drive the expression of the viral proteins 
required for replication.  
 
Following the characterization of an HCV genotype 2a isolate derived from a Japanese 
patient with fulminant hepatitis designated (JFH-1), another cell culture based system was 
developed (222-224). Unlike before, this system was capable of emulating the full viral 
lifecycle. However, to increase infectivity, multiple chimeras were created, of which one is 
JC1. JC1 is a chimeric hybrid combining the core to NS2 coding region of another genotype 
2a isolate J6 and the NS3 to NS5B coding region of JFH-1. This combination yields a viral 
titer 1000 times more efficient than the original JFH-1 isolate (225).  
 
Both of these models have had undergone multiple iterations to provide adaptations for 
screening and microscopy purposes. This includes firefly luciferase (Fluc) reporter and green 
fluorescent protein (GFP) tagged alternatives. It should be noted that these culture systems 
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typically use Huh7 derived hepatoma cell lines, which lack immune (226, 227) and metabolic 
(228) features of primary human hepatocytes, and consequently confer a notable disadvantage 
when compared to other models for the study of HCV.  
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Figure 3. Overview of cell culture based systems for the study of HCV. 
(A) Structures of HCV replicons. (a) Schematic presentation of the HCV genome. 5′ and 
3′NTR are indicated by white bars. (b) and (c) Structures of bicistronic selectable subgenomic 
replicons. They are composed of the HCV 5′NTR directing translation of the neo gene, the 
IRES of the encephalomyocarditis virus (E-I), the HCV replicase genes NS3–NS5B (a) or 
NS2–NS5B (b) and the 3′NTR. (d) Structure of a subgenomic Con1 reporter replicon. (e) 
Structure of a selectable reporter replicon. This construct encodes a luciferase–ubiquitin–
neomycin phosphotransferase fusion protein in the first cistron. (f) Structure of a 
monocistronic reporter replicon. The entire polyprotein is translated by the HCV IRES. (B) 
Structure of JFH-1 derived genomes. (a) Chimeric genomes are composed of the region 
encoding core to NS2 of HCV isolate J6 fused to the remainder of the JFH-1 isolate. This 
highly competent J6/JFH-1 chimera is called Jc1. (b) Schematic representation of a bicistronic 
full length JFH-1 reporter genome. The HCV 5′NTR directs translation of the firefly luciferase 
gene (Luc) whereas translation of the HCV polyprotein is under the control of the EMCV 
IRES (E-I). (c) Schematic diagram of a monocistronic Renilla luciferase (RLuc) reporter 
genome. (d) Structure of a monocistronic Jc1 reporter virus applicable for live cell imaging. 
The gene encoding GFP is inserted in-frame into domain 3 of NS5A. (permission from Woerz 
I, and Lohmann V, J of Viral Hepatitis., 2009. Copyright Journal compilation © 2009 
Blackwell Publishing Ltd) (229)     
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5. Bioluminescence Resonance Energy Transfer (BRET) 
 
While the yeast two-hybrid system has been widely used to identify protein-protein 
interactions (PPIs), resonance energy transfer methods have presented a few advantages. 
Unlike the classical yeast two-hybrid system that is limited to detecting interactions within the 
nucleus (230) and that therefore forgo protein processing and compartmentalization, these 
alternatives can detect interactions which depend on post-translational modifications.  
 
 BRET, first used in 1999 to study the dimerization of proteins implicated in the 
circadian cycle of cyanobacteria (231), is a technique that exploits the non-radioactive energy 
transfer between a bioluminescent energy donor protein and a fluorescent energy acceptor 
protein. Compatible with live cell settings, BRET can be used to determine PPIs that more 
easily reflect what occurs naturally within a cell and it also represents an unprecedented 
method to observe membrane PPIs. For instance, in a previous report where novel HCV 
protein interactions were identified (232), the inclusion of the interaction between NS4B and 
NS5A, which are located at the ER and at LDs respectively, and the exclusion of the 
interaction between NS3/4A and p7, which are both localized to the mitochondria, within an 
updated HCV interaction network attest for the specificity of BRET and its independence from 
protein localization.  
 
While Renilla reniformis luciferase (Rluc) is always the energy donor different 
iterations of BRET such as BRET
1
, BRET
2
 and eBRET, utilize different combinations of 
substrates and energy acceptor proteins for their associated advantages (233). These include 
greater emission peak separation which reduce background effects and greater signal duration 
which facilitate time dependent experiments. These advantages are, however accompanied by 
inconveniences related to cell viability and the requirement of more sensitive equipment. 
Nevertheless, for the sake of this explanation, the case of BRET
1
 is specifically addressed. 
Indeed, Rluc, following oxidation of its cell permeable substrate coelanterazine H, is able to 
emit a photon at a maximal wavelength of 480 nm (234). Upon excitation by photons up to a 
 36 
maximal wavelength of 514 nm, the yellow fluorescent protein (YFP) emits itself a photon at a 
maximal wavelength of 527 nm. Given the differing wavelengths of donor and acceptor 
protein photon emissions, the energy transfer can easily be quantified by calculating the ratio 
between the intensities of photons emitted by YFP and Rluc. This ratio is referred to as the 
BRET signal. However, because the energy transfer is inversely proportional to the sixth 
power of the distance between donor and acceptor dipoles (235), energy transfer is only 
detectable when both YFP and Rluc are within 10–100 Å of each other and when YFP and 
Rluc tagged proteins are properly oriented. As a result, if YFP and Rluc tagged candidates do 
not interact, only bioluminescence (Rluc emission) is detected. Conversely, if both candidates 
interact, both bioluminescence and fluorescence (YFP emission) are detected. 
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Hypothesis & Objectives 
Hypothesis:  
The previous optimization of live cell based assays using bioluminescence resonance 
energy transfer (BRET) technology had established a comprehensive hepatitis C virus (HCV) 
protein interaction network and had subsequently revealed an unreported NS3/4A-NS3/4A 
interaction (232). Given the existing proteolytic activity of NS3/4A and the novelty of the 
NS3/4A-NS3/4A interaction, the development of HCV inhibitors based on PPI modulation 
had potential. The premise of my Master’s project is that inhibitors identified through BRET 
based assays constitute a novel class specific to HCV and function through a unique 
mechanism different from drugs already available on the market. 
 
Objective: 
The objective of my project is to characterize novel HCV inhibitors identified through 
BRET based assays that can be used in combination with currently available inhibitors. This is 
achieved through the evaluation of compound therapeutic potency and through the 
confirmation of a novel inhibitory mechanism via resistance profiling.  
 
Aims: 
- In vitro characterization of the resistance profile of a lead compound acting on the 
replication of HCV. 
- Study lead compound induced modulation of previously identified cellular partners 
that potentially contribute to viral replication.  
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Experimental Procedures 
Cell culture 
The 293T, and Huh7.5 cell lines were cultured in Dulbecco's modified Eagle's medium 
(DMEM) containing 10% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 
mM l-glutamine, and 1% nonessential amino acids (all from Wisent) at 37 °C in an 
atmosphere of 5% CO2. Cells were transfected with linear (25-kDa) polyethylenimine (PEI; 
Polysciences) (236) or Lipofectamine 2000 (Invitrogen) as described by the manufacturer. 
Cell populations of HEK 293T stably harbouring the pIFNB1-LUC and of Huh7.5 stably 
harbouring the pEF1α-LUC were produced after selection with 200μg/ml of hygromycin B 
(Wisent) and were previously described (237). Huh7 cells stably expressing a reporter Con1 
subgenomic replicon (Huh7-Con1-Fluc) (221) were a gift from Ralf Bartenschlager 
(University of Heidelberg) and were maintained in complete DMEM with 1 μg/μL G418 
(Multicell). 
Expression vectors 
KPNB1 and HSP60 cDNA were purchased from GE Dharmacon/Open Biosystems. Following 
PCR-amplification, PCR products were cloned into either pcDNA3.1_MCS(MB)-eYFP or 
pCDNA3.1_FLAG-MCS(MB) expression vectors using Pfl23II/NotI enzymes (236). 
3xFLAG-NS3/4A, MYC-NS3/4A, FLAG-eYFP, NS3/4A S139A, pIFNB1-LUC and pISG56-
LUC were previously described (95, 236, 238-240). All constructs were verified by the 
genomics platform at the Institute of Research in Immunology and Cancer (Montreal, Qc, 
Canada) and by subsequent Western Blot analysis when applicable. 
BRET assays 
293T cells were transfected in 24-well plates with 5 ng/well of the DNA construct coding for 
the BRET donor (Rluc-x) and increasing amounts (0 to 200 ng/well) of the DNA construct 
coding for the BRET acceptor (eYFP-x), and total DNA was completed to 1 μg using salmon 
sperm DNA (Invitrogen). At 48 hours post-transfection, cells were harvested in Dulbecco's 
modified Eagle's medium and washed twice with PBS. For each sample, two aliquots of 1 × 
 39 
10
5
 cells were distributed to wells of a 96-well microplate (Costar 3912; Corning). Total eYFP 
expression was measured using a Flex Station II (Molecular Devices), with an excitation 
wavelength at 485 nm, an emission filter at 535 nm, and a cutoff of 530 nm. The luciferase 
substrate coelenterazine H (Lucigen Corporation) was then added to give a final concentration 
of 5 μM, and emissions of luminescence and fluorescence were measured simultaneously 
using a Mithras LB940 (Berthold Technologies). Filters were set to 485 ± 10 nm for luciferase 
emission and 530 ± 12.5 nm for eYFP emission. BRET ratios were calculated as described by 
Angers et al (241) 
 
HCV replication 
9-13 Huh7 cells were previously described (221) and stably express the genotype 1b Con1 
subgenomic replicon. This bicistronic replicon expresses the neomycin phosphotransferase 
through the HCV IRES, while NS3-NS5B polyprotein production is under the control of the 
encephalomyocarditis virus (EMCV) IRES. The reporter Huh7 cells stably express the Con1 
subgenomic replicon as well as both neomycin resistance and Firefly luciferase (221).  
 
EC50 and CC50 assays 
For EC50 and CC50 assays, Huh7 stably expressing the Con1 subgenomic replicon (221) and 
Huh7.5 stably expressing pEF1α-LUC (236) were seeded in 96-well plates at a density of 
15,000 cells in phenol-red free DMEM and incubated at 37°C in an atmosphere of 5% CO2. 
On the second day, gradually increasing concentrations of UM42811 were added to replicate 
well series; DMSO was used as a negative control. On the third day, 10 μl of alamarBlue 
reagent (Invitrogen; diluted 1:4 in PBS) was added to each well and following a 4 hour 
incubation 37°C, supernatant were collected in black 96-well plates. Supernatant fluorescence 
at 595 nm (excitation wavelength, 531 nm) was measured with an EnVision plate reader 
(PerkinElmer). A control plate with medium only (no cells) or alamarBlue only was used to 
determine the background that was subtracted from the fluorescence value. Adherent cells 
were washed twice with ice-cold phosphate-buffered saline (PBS; Wisent), and subsequent 
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cell lysis and firefly luciferase readings were perfomed in a 100 mM Tris acetate, 20 mM Mg 
acetate, 2 mM EGTA, 3.6 mM ATP, 1% Brij 58, 0.7% β-mercaptoethanol and 45 μg/ml 
luciferine pH 7.9 buffer. 
Selection of HCV replicon escape resistant variants  
Huh7 stably expressing the Con1 subgenomic replicon (221) were seeded in 6 well plates at a 
density of 150,000 cells in DMEM containing G418 at a concentration of 1 μg/μL G418 
(Multicell). On day 2, compound UM42811 dissolved in DMSO was added at indicated 
concentrations. On day 4, cells were transferred into 10 cm plates with fresh DMEM, 
compound UM42811 and G418. Media was renewed weekly, and inhibitors renewed twice a 
week. On day 21, cell colonies were picked and left to expand in 24 well plates containing 
fresh media, and both selection reagents. On day 35, RNA was extracted; 5 RT PCR reactions 
per clone were performed; resulting samples were put into an equimolar mixture, sonicated 
into 75-200 bp fragments and subsequently sent to the Illumina HiSeq platform at McGill 
University and Génome Québec Innovation Centre (Montreal, Qc, Canada) for deep 
sequencing. 
 
Production of mutated HCV enzymes  
NS3/4A mutants K617N, I615M and L14F were individually generated via site-directed 
mutagenesis within the subgenomic replicon and the respective expression vectors using the 
Q5® kit (NEB, Ipswich, MA, USA). Substitutions were created by incorporating the desired 
nucleotide change in the center of the forward primer, including at least 10 complementary 
nucleotides on the 3´side of the mutation. The reverse primer was designed so that the 5´ ends 
of the two primers anneal back-to- back. PCRs were performed in a MasterCycler Gradient 
(Eppendorf, Hamburg, Germany) set at the following: 3min. incubation at 98°C; 25 repeating 
cycles of 10s at 98°C, 30s at 68°C, and 1min./1kb vector length at 72°C; and 3min. incubation 
at 72°C. All constructs were verified by the genomics platform at the McGill University and 
Génome Québec Innovation Centre (Montreal, Qc, Canada) and by subsequent Western Blot 
analysis when applicable. 
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shRNA gene silencing 
shRNAs from MISSION TRC shRNA lentiviral library (Sigma-Aldrich) were used as 
followed: shRNA targeting KPNB1 (TRCN0000123189), HSP60 (TRCN0000029446), or 
shRNA non-target (NT). shRNA were transfected in combination with a standard packaging 
mix (1.5 μg pMDLg/pRRE, 1.5 μg pRSV-REV and 3 μg pVSVg) as previously described 
(242). 
 
Functional firefly luciferase assays 
For assays in 96-well plates, cells were seeded in white 96-well plates at a density of 5,000 
HEK 293T in 100 μl of complete phenol-red free DMEM. For conditions with shRNA, 
polybrene was added to the phenol-red free DMEM at a concentration of 4 μg/ml. Infection 
with lentivirus encoding shRNA were carried out immediately after cell seeding at a MOI of 
10 and incubated at 37°C in an atmosphere of 5% CO2. On the second day, cells in each well 
were transfected with 50 ng of pIFNB1-LUC or pISG56-LUC and 200 ng of the concerned 
protein expression vector. BILN 2061 and UM42811 were added at the indicated 
concentrations immediately following transfection; DMSO was used as control. On the third 
day, Cells were infected with 100 HAU/ml of SeV (Cantell Strain, Charles River Labs) or 
stimulated with recombinant IFN-α 2A (Sigma-Aldrich) for 16 hours before cell lysis and 
firefly luciferase reading which were performed in a 100 mM Tris acetate, 20 mM Mg acetate, 
2 mM EGTA, 3.6 mM ATP, 1% Brij 58, 0.7% β-mercaptoethanol and 45 μg/ml luciferine pH 
7.9 buffer. All infections were performed in an enclosed class II cabinet. 
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Western blot analysis 
Cells were washed twice with ice-cold phosphate-buffered saline (PBS; Wisent), harvested 
and lysed in 10mM Tris-HCl, 100mM NaCl, 0.5% Triton X-100, pH7.6 with EDTA-free 
Protease Inhibitor Cocktail (Roche). Cell lysates were clarified by centrifugation at 13,000 g 
for 15 min at 4 °C and subjected to sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE). 
Western Blot analysis was performed using the following antibodies: ACTIN was purchased 
from Chemicon International (Billerica, MA MAB1501R); FLAG was purchased from Sigma 
(St-Louis, MO, USA, F3165); KPNB1, and NS3 were purchased from Abcam (Toronto, 
Ontario, Canada, ab2811, ab13830); ISG56 was purchased from Novus Biologicals (Oakville, 
ON, NBP1-32329); HSP60 was purchased from Cell Signaling Technology, Inc, (Danvers, 
MA, 2859); GAPDH was purchased from RDI (Flanders, NJ, TRK5G4-6C5); and MYC, and 
IRF3 were purchased from Santa Cruz Biotechnology (Dallas, TX, sc-789, fl-435). The 
antibody for PARP1 and Sendai Virus was a kind gift from MJ. Hébert and M. Servant, 
respectively. HRP-conjugated secondary antibodies were from Bio-Rad. The 
chemiluminescence reaction was performed using the Western Lighting Chemiluminescence 
Reagent Plus (PerkinElmer).  
 
Co-immunoprecipitation 
For co-immunoprecipitation, FLAG-tagged protein expressing cells were harvested and lysed 
as described above. Resulting cell extracts were adjusted to 1 mg/ml and subjected to IP as 
follows: pre-clearing of the lysates was done by incubating lysates with 40 μl of 50:50 slurry 
of immunoglobulin G-Sepharose (GE Healthcare) prepared in the lysis buffer with IgG beads 
for 1 hour. Pre-cleared lysate were immunoprecipitated by adding 20 μl of M2 anti-FLAG 
affinity gel (Sigma-Aldrich) prepared in TBS buffer (50 mM Tris-HCl, 150 mM NaCl, pH 
7.4) overnight as described by the manufacturer. Immunoprecipitates were washed five times 
in lysis buffer. Elution was performed using 250 ng/μl purified FLAG peptide for 45 min at 4 
°C (Sigma-Aldrich). Eluates were analyzed by Western Blotting.  
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Results 
1. Investigation of pairwise interactions between HCV proteins 
 
In a previous work with an aim of identifying new functional HCV protein interactions 
(232), all possible interaction combinations between pairs of HCV proteins excluding those 
which are structural were tested using BRET. This included a total of 21 possible interactions 
between p7, NS2, NS3/4A, NS4B, NS5A, and NS5B. To identify and characterize new 
interactions between HCV proteins, BRET saturation curves were performed by expressing 
fixed level of donor fusion constructs (Rluc) with increasing amounts of acceptor fusion 
constructs (eYFP). In a BRET saturation curve, the y-axis represents the BRET signal which is 
the ratio of the light intensity emitted by YFP over that emitted by Rluc and the x-axis 
represents the quantitative protein ratio of YFP over Rluc (Figure 4A). Because the efficiency 
of BRET is dependent on the inverse sixth power of intermolecular separation and the relative 
orientation of the donor and acceptor transition dipole moments (235), BRET can most 
accurately measure molecular proximity at 10–100 Å in which case interacting dipoles are 
deemed sufficiently close to infer a definitive interaction. In this way, a non-linear curve is 
representative of the specific engagement of both YFP and Rluc fusion protein partners and is 
the means by which specific protein-protein interactions are discriminated from non-specific 
interactions. The maximum signal obtained for a saturation curve is called BRETmax and varies 
according to orientation and distance between the energy donor and the acceptor within the 
dimer, whereas the relative affinity between the fusions proteins is reflected by the 
quantitative YFP/Rluc protein ratio required to obtain 50 % of the BRETmax (BRET50) (243). 
Results from the BRET pairwise interactions are summarized in a matrix table (Figure 4B). 
Interactions previously reported by the HCVpro database (244) and reconfirmed through the 
BRET assay are colored in green, whereas interactions which failed to be reconfirmed are 
colored in yellow. Uncharacterized interactions which were newly identified by BRET are 
colored in blue and outlined in red. As NS4A is considerably small relative to the size of an 
eYFP or a Rluc tag and as it mainly serves as a cofactor to NS3 ensuring its protease function 
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and subcellular localization, BRET experiments were performed using constructs encoding the 
entire NS3/4A heterodimer rather than constructs encoding each individual protein of the 
protease complex. BRET analysis reproduced 13 previously reported interactions while failing 
to reproduce the NS2-NS5B interaction. Though the quality of the specific interactions varies 
(data not shown), four new pairwise specific interactions between HCV proteins were 
identified: the interaction between heterodimers of NS3/4A, the latter’s interaction with NS2 
and NS5A, along with the interaction between NS4B and p7. 
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Figure 4. Bioluminescence resonance energy transfer identifies novel HCV protein-
protein interactions 
 (A) Working principle of a BRET saturation graph.  Example 3D structures of YFP 
and Rluc fusion proteins (left). BRET saturation graph (right): X-axis represents quantitative 
ratio between YFP and Rluc fusion proteins; Y-axis represents BRET signal or ratio between 
fluorescence and bioluminescence. (B) Reported and/or BRET identified interaction matrix 
between HCV proteins p7, NS2, NS3/4A, NS4B, NS5A, and NS5B. 
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2. Homodimerization of the NS3/4A heterodimer 
 
The BRET saturation curve obtained for the pairing of the NS3/4A protease with itself 
increases non-linearly according to increasing protein ratios, representing the specific 
engagement of the Rluc-fused protein with its eYFP-fused counterpart (Figure 5A). As 
negative controls, TAP2, an ER-localized protein not part of the HCV replication complex 
which in conjunction with TAP1 forms a heterodimer implicated in the delivery of cytosolic 
peptides to the ER lumen, and eYFP were used. The saturation curve obtained with TAP2-
Rluc and eYFP-NS3/4A leads to a linearly increasing and weak BRET signal resulting from 
random collisions between the two fusion proteins (orange curve in Figure 5A). This control 
demonstrates that the BRET technique is able to distinguish direct protein-protein interactions 
from interactions due to the similar subcellular localization. The NS3/4A serine protease being 
one of the better and earlier characterized proteins of HCV, it was interesting that the BRET 
system was able to identify an uncharacterized interaction of the protein with itself. Therefore 
to confirm this interaction, a co-IP experiment was performed (Figure 5B). 293T cells were 
co-transfected with Myc-NS3/4A and either FLAG-NS3/4A or TAP1-FLAG and lysates were 
immunoprecipitated with anti-FLAG coated beads 48 hours post-transfection. FLAG 
immunoprecipitates were immunobloted with an anti-Myc antibody (upper panel) and an 
anti-FLAG antibody (lower panel). It was observed that Myc-NS3/4A co-immunoprecipitated 
with FLAG-NS3/4A (lanes 3-4) but not TAP1-FLAG (lanes 1-2), therefore confirming BRET 
results. Together, BRET and co-IP experiments demonstrate a specific interaction between 
NS3/4A heterodimers.  
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Figure 5. Specific interaction between NS3/4A heterodimers 
(A) BRET saturation curves. In green, curve for N-terminally tagged NS3/4A fusion 
proteins. In red, curve with an eYFP negative control. In orange, curve with C-terminally 
tagged TAP2 colocalization negative control. X-axis represents quantitative ratios between 
YFP and Rluc fusion proteins; Y-axis represents BRET signal or ratio between fluorescence 
and bioluminescence. (B) HEK 293T cells are co-transfected with either TAP1-FLAG and 
Myc-NS3/4A or FLAG-NS3/4A and Myc-NS3/4A. 48h post-transfection, co-
immunoprecipitation experiment using anti-FLAG coated beads is carried out. Both total 
lysate (input) and immunoprecipitated lysate (IP) are immunoblotted with anti-Myc and anti-
FLAG antibodies. 
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3. Implementation of a BRET HTS assay 
 
With the protease activity of NS3/4A being largely characterized and with potent 
inhibitory compound BILN2061 targeting this mechanism readily available, a BRET HTS 
assay using a library of compounds with potential protein-protein interaction (PPI) modulators 
was developed to investigate the newly identified NS3/4A homodimeric interaction. A HTS 
adapted version of the BRET assay mentioned in the methods was performed in 384-well 
plates at a cell density of 10,000 cells per well using transient transfection of both eYFP and 
Rluc fusion plasmids (Figure 6A). Prior to initiating HTS against the compound collection, a 
smaller scale BRET assay was performed on reported/identified NS3/4A-NS3/4A, NS5A/D1-
NS5A/D1, NS4B-NS4B and NS3/4A-NS5A interactions to evaluate the reproducibility of 
BRET
1
 ratios measured in 384 well plates (Figure 6B). Z-factors (245), denoted by a value <1 
to indicate the ease with which sample values can be distinguished from control values within 
HTS based on standard deviations and mean value separation, were calculated for each of the 
interactions. Z-factors for each of the interactions were found to be well above 0.5 (Figure 6B) 
which is indicative of optimal suitability of a configured assay for HTS (245). Similarly, 
validation of a HTS assay is commonly determined using Z’ factor calculations (245). Unlike 
the Z factor, Z’ factor is a statistical parameter which accounts for the dynamic range and 
variation between positive and negative controls rather than those between a control and a 
sample condition. In this respect, Z’ factor is more a reflection of the overall assay quality. 
Knowing that protease function is the only properly characterized function of NS3/4A, and 
inferring that the observed NS3/4A dimer interaction plays a role towards this end, potent 
protease inhibitor BILN2061 at 2 µM was taken as the positive control, while 0.5% DMSO was taken 
as the negative control. Z’ factor for this BRET HTS assay was found to be above 0.5 (data not shown) 
and thus the full scale HTS was initiated. With the collaboration of the Institute of Research in 
Immunology and Cancer (IRIC)’s screening platform, a library of compounds comprised of 
approximately 110,000 compounds (details listed in Figure 6C) was tested against the NS3/4A dimer 
interaction and the NS5A/D1 dimer interaction as an additional screen. Because HCV antiviral drugs 
effective within the nanomolar range are acceptable (246), HTS using compounds at 10 µM was deemed 
suitable for the identification of compounds eligible for lead optimization. From the screening data, 
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the average of all compounds tested for NS3/4A dimer in BRET signal percentage of 
inhibition was 4% ± 18.6% (Figure 6D). Based on these average activity values, the cut-off for 
the identification of hit compounds was established at ± 50% of the control (~2.5 times the 
standard deviation). By simultaneously screening both NS3/4A and NS5A/D1 dimer targets, 
hit compounds identified by their modulation of the BRET signal in primary assay were 
prioritized based on selectivity as determined by the lack of activity within the NS5A/D1 
dimer targeted BRET HTS assay (<30% and >-30% BRET signal inhibition). Compounds 
were also excluded based on inherent bioluminescence quenching (>95% Rluc quenching) 
(Figure 6D). A total of 105 potential NS3/4A PPI inhibitors, and 5 potential NS3/4A PPI 
activators were identified. 
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Figure 6. Identification of potential NS3/4A PPI modulators through a BRET HTS 
assay 
(A) Schematic representation of the BRET HTS screen. HEK 293T cells were 
transfected with Rluc- and eYFP-fusion encoding plasmids. After 24 hours, cells were 
harvested and distributed in 384-well plates before the addition of chemical compounds to a 
final concentration of 10 µM. Twenty-four hours later, coelanterazine H was added at a final
 
concentration of 5 µM, and emission of luminescence and fluorescence
 
were measured 
simultaneously to calculate the BRET signal. (B) BRET
1
 ratios obtained for 
reported/identified NS3/4A-NS3/4A, NS5A/D1-NS5A/D1, NS4B-NS4B, and NS3/4A-NS5A 
interactions in a preliminary 384-well plate test. Z-factors for each interaction screen are 
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calculated. (C) Detailed breakdown of the library of compounds tested within the full-scale 
BRET HTS assay targeting the NS3/4A-NS3/4A interaction. (D) Distribution of the NS3/4A-
NS3/4A BRET
1
 ratio inhibition obtained in the primary screen: X-axis represents the % 
inhibition relative to the negative control; Y-axis represents the number of compounds found 
to provide a given % inhibition. Cutoffs of 50% BRET
1
 modulation for the NS3/4A-NS3/4A 
interaction (with additional restrictions of bioluminescence quench < 95% and BRET
1
 < 30% 
modulation for the NS5A/D1-NS5A/D1 interaction) allowed the selection of 105 specific 
inhibitors and 5 specific activators. 
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4. Validation and antiviral characterization of lead compound 
UM42811 
 
To validate the hits from the primary screen, a replicate screen using the 110 hits was 
performed (data not shown). Primary screen hits that failed to meet selection criteria during 
the replicate screen were rejected, and the compound with the highest absolute NS3/4A PPI 
modulation was selected for further validation and antiviral characterization. O5-{[3-(2-
chlorophenyl)-5-methylisoxazol-4-yl]carbonyl}-1,3-benzodioxole-5 carbohydroximamide 
which will henceforth be referred to as compound UM42811 for the sake of simplicity and 
readability (chemical structure shown in Figure 7A) was confirmed as a NS3/4A PPI activator 
in the replicate screen by demonstrating anew an inhibition less than -60%, an inhibition 
greater than -30% on NS5A/D1 and a quench less than 95%. A 10-point titration BRET assay 
(duplicate: 0.02 to 10 µM) was developed for further validation and dose-response evaluation 
of the lead compound. HEK 293T cells were transfected with eYFP and Rluc NS3/4A fusion 
expression vectors for 48 hours and incubated in the presence of BILN2061 or UM42811 for 
24 hours to evaluate their effect on the BRET signal. Potent protease inhibitor BILN2061 was 
used as a PPI modulator control given its ability to decrease NS3/4A dimer-mediated BRET 
signal (left panel Figure 7B). The decrease of the BRET signal reflects a change in dimer 
orientation between the mature autocleaved form of NS3/4A (without bound BILN2061) and 
the immature uncleaved form of NS3/4A (with bound BILN2061), and demonstrates the 
sensitivity of the BRET readout to measure conformational changes within dimers. NS5A/D1 
dimer-mediated BRET signal (orange curve) was used as a compound specificity control. 
From these titration curves, BRET inflection points (BRETIP) can be determined. Significant 
changes were observed in the BRET signals with BRETIP values near 0.2 µM for BILN2061 
and values within the lower micromolar range for compound UM42811. Because the 
autocleavage activity of NS3/4A can induce conformational changes within the homodimer 
and create unwanted BRET signal noise, a NS3/4A protease defective mutant constructs 
(NS3/4A S139A – green curve) were used alongside wild type NS3/4A constructs. UM42811 
predominantly increased the BRET signal mediated by protease defective NS3/4A dimers than 
wild type NS3/4A dimers. To evaluate the pharmacological and antiviral properties of lead 
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compound UM42811, biologically relevant models of HCV replication and cellular fitness 
were used. Huh7 cells bearing HCV subgenomic reporter Con1 replicon were used to assess 
antiviral activity and half-maximal response (EC50) of UM42811 at inhibiting HCV replication 
using serial diluted concentration spanning 0.01 to 30 µM (left panel Figure 7C). Similarly, 
Huh7 stably expressing an EF-1 alpha promoter driven firefly luciferase and the respective 
mitochondrial reductive capacities measured by alamar blue in both cells were used to 
determine the cytotoxicity (alamar blue of Con1 bearing cells shown in right panel Figure 7C). 
Computer generated analysis of the HCV replication inhibition and cytotoxicity determined 
EC50 to be 0.59µM and CC50 to be 28.35µM. The therapeutic index, given as the CC50/EC50 
ratio, was determined to be 48.05 demonstrating the pharmacological potential of compound 
UM42811 as a novel anti-HCV agent. The inhibition of an EF-1 alpha promoter driven 
luciferase in Huh7 cells was also determined to be around 28µM (data not shown). This 
demonstrated that the submicromolar antiviral activity of dioxole-containing compound 
UM42811 on HCV replicon was not due to the inhibition of firefly luciferase activity (247). 
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Figure 7. Validation and antiviral characterization of lead compound UM42811 
(A) Chemical structure of lead compound UM42811 identified as a modulator of BRET 
NS3/4A homodimerization signal. (B) Dose-response evaluation of BILN2061 and UM42811 
in cell-based BRET dimerization assays. NS3/4A S139A is a protease inactive mutant. (C) 
Dose-response evaluation of UM42811 in reporter Con1 subgenomic replicon denoting EC50 
(left) and in alamar blue assay denoting cellular fitness CC50 (right). 
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5. Characterization of UM42811 resistance profile reveals 
mutations located at the surface of the C-terminal NS3 helicase 
subdomain 
 
To ascertain UM42811 as a NS3/4A-targeted inhibitor that is mechanistically different 
from current protease inhibitors, selection of cells containing UM42811-resistant HCV 
replicons was performed. Huh7 cells bearing HCV subgenomic Con1 replicon were 
maintained in media containing G418 and UM42811 at either 10 µM or 20 µM for 3 to 5 
weeks. Following prolonged exposure to UM42811, replicon bearing cells cured by the 
UM42811 were cleared in presence of 1 mg/ml G418 due to the loss of the neo
R
 (G418 
resistance) gene encoded by the HCV replicon. Cells refractory to viral inhibition, due to the 
selection of resistant replicon variants, were either stained for proper colony visualization or 
lysed. RNA was extracted from cell lysates and RT-PCR was performed using HCV specific 
primers. Genetic samples were then sonicated into 75 to 200 base pair fragments and 
subsequently sent to the Illumina HiSeq platform at McGill University and Génome Québec 
Innovation Centre (Montreal, Qc, Canada) for deep sequencing analysis. Crystal violet 
staining of emerging treatment-resistant colonies (Figure 8A) provided a preliminary 
quantitative measure of UM42811’s ability to inhibit viral replication and to suppress 
emergence of resistance. 10 µM concentration of UM42811, which is much greater than the 
previously determined EC50 and within range of NS3/4A homodimer BRET signal activation, 
was discernably able to inhibit HCV replication when compared to the DMSO control. At a 20 
µM concentration, which is lower than previously determined CC50, emergence of resistant 
colonies was completely suppressed and results were visually comparable to a Huh7 killing 
control. Deep sequencing analysis revealed a number of mutations throughout the HCV 
polyprotein. The 9 most common mutations and their associated frequencies are shown in 
Figure 8B. Though mutations found in non-structural proteins other than NS3 were relatively 
frequent (<1% to 6%), they were less significant than mutations occurring in NS3 with I615M 
and K617N alone accounting for 19% and 23% of samples respectively. Nonetheless, amino 
acid sequence alignment using a compiled database of full-length HCV genomes was 
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performed to analyse variation frequency at each given position and to provide greater 
stringency for the identification of potential resistance mutations. Though NS3/4A I615M and 
K617N, NS4B P197S, NS5A E420K and E422G, and NS5B S196A were naturally 
uncommon and as such weighted more heavily, given the nature by which UM42811 was 
selected (through an NS3/4A dimerization BRET screen) and the greater frequency of 
associated mutations on NS3/4A, resistance studies were focused on NS3/4A associated 
mutations. As displayed on the NS3/4A 3D structure (Figure 8C), I615M and K617N were 
mapped at the surface of the C-terminal helicase domain while L14F was mapped at a region 
involved in membrane anchoring. Because these mutations are not associated with protease 
inhibitors resistance (248, 249), and given the feasibility of resistance mutations at accessible 
surface residues and at residues associated with potential functional alterations, these studies 
suggest that UM42811 specifically targets NS3/4A and differs mechanistically from protease 
inhibitors.  
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Figure 8. Characterization of UM42811 resistance profile reveals mutations located at 
the surface of the C-terminal NS3 helicase subdomain 
(A) Crystal violet staining of BILN2061 and UM42811 emerging escape variant 
colonies following 3 week inhibitor exposure. (B) Schematic representation of the HCV 
polyprotein (top-down) punctuated by the localization of the most common mutations 
identified following deep-sequencing and occurring after 35 day exposure to UM42811. (C) 
3D schematic of the NS3/4A heterodimer. The C-terminal helicase domain (grey), the N-
terminal protease domain (blue), the NS4A cofactor (yellow), the catalytic triad (purple) and 
emerging resistance mutations K617N (orange), I615M (red), and L14F (green) are presented.  
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6. Generation of NS3/4A mutant fusion proteins and of mutant 
HCV replicon DNA precursors 
 
For further characterization of the UM42811, emerging resistance mutations K617N, 
I615M and L14F were generated as fusion proteins within eYFP and FLAG expression 
vectors (Figure 9A) as well as within HCV replicon. To this end, different strategies were 
contemplated for the substitution of single nucleotides within the NS3/4A coding sequence.  
 
Traditional PCR site-directed mutagenesis in which sequential exponential 
amplification by PCR produces a fragment containing the desired mutated sequence flanked 
by conveniently placed restriction sites was found to be largely inefficient at introducing a 
point mutation within particularly large coding sequences such as that of HCV subgenomic 
replicon expressing DNA vectors. Whole plasmid mutagenesis which is a relatively simpler 
process was more successful to this end. Rather than generating fragments which needed to be 
inserted using recombinant molecular biology techniques, this approach to site-directed 
mutagenesis instead generated a nicked, circular DNA. Template DNA and mutated plasmids 
generated in vitro are discriminated based on methylation. Because only biosynthesized DNA 
is methylated, restriction enzymes such as DpnI were used to eliminate unmutated template 
DNA.  
 
After a series of optimizations of primer design, substitutions were achieved by 
incorporating the desired nucleotide change in the center of the forward primer, including at 
least 10 complementary nucleotides on the 3´side of the mutation as displayed in Table I. The 
reverse primer was designed so that the 5´ ends of the two primers annealed back-to-back with 
no overlap. PCRs were performed in a MasterCycler Gradient (Eppendorf, Hamburg, 
Germany) set at the following: 3min. incubation at 98°C; 25 repeating cycles of 10s at 98°C, 
30s at 68°C, and 1min./1kb vector length at 72°C; and 3min. incubation at 72°C. Mutated 
expression vectors and replicon expressing DNA vectors were assessed for their purity and 
their sequences were verified at the genomics platform at McGill University and Génome 
Québec Innovation Centre (Montreal, Qc, Canada) (Figure 9B-C-D). While generating 
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replicon expressing DNA vectors containing mutated enzymes was successful, introduction of 
in vitro transcribed subgenomic RNA into Huh7/7.5 cells was largely unsuccessful based on 
lack of luciferase activity and viral protein expression (data not shown) despite optimization 
attempts of classical and adapted protocols (250-252). Of the three subgenomic replicons 
bearing a potential punctual resistance mutation, only the one bearing an I615M was 
successfully reintroduced into Huh7.5 cells. Though these cells still lacked luciferase activity, 
because the replicon system is bicistronic and because the luciferase gene is often inexplicably 
lost over time, real-time PCR (qPCR) was performed directly on the HCV IRES to confirm its 
presence and on the luciferase gene to confirm its loss (data not shown). Though these results 
are fragmentary, it demonstrated that the lack of luciferase activity was not due to an 
incompatibility of this mutation with the replication of the subgenomic replicon.    
 
Mutation Primer 
Orientation 
Sequence 
L14F Forward CCAACAGACGCGAGGCCTA*T*TTGGCTGCATCATCACTAGC 
Reverse GAGTAGGCCGTAATAGGCGCCATGGTATTATCG 
I615M Forward GGTTACTACCACACACCCCAT*G*ACCAAATACATCATGGC 
Reverse TCGTTTTGAACGGCTCCCAGCCTATACAGC 
K617N Forward CCATAACCAA*T*TACATCATGGCATGCATGTC 
Reverse GGTGTGTGGTAGTAACCTCGTTTTGAACGGC 
Table I. Generation of single point mutations within HCV NS3 
Primers used to generate potential resistance mutations to UM42811 within NS3/4A. 
Site directed mutagenesis was performed with Q5® kit (NEB, Ipswich, MA, USA). In red are 
the nucleotide substitutions which generate the desired amino acid changes.  
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Figure 9. Mutated NS3/4A expression vectors and mutated replicon sequences 
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(A) Expression vector diagrams of eYFP-NS3/4A and 3xFLAG-NS3/4A fusion 
proteins. Red stars indicate the approximate location of I615M, K617N, and L14F mutations. 
A dual Cytomegalovirus and T7 promoter drives the expression of the fusion protein. An 
Ampicillin resistance gene is included to allow selection upon bacterial amplification.  
Nucleotide sequence of I615M (B), K617N (C), and L14F (D) NS3/4A mutants as analyzed 
by the Sequencing Services at McGill University and Génome Québec Innovation Centre 
(Montreal, Qc, Canada). Viewed with the CLC Sequence Viewer (CLC bio, Aarhus, 
Denmark) software. Coding sequences for wild type NS3/4A are shown at the very top with 
the corresponding amino acid sequence displayed underneath. Chromatographs are also shown 
for mutant sequences (and wild type in the panel A) as indicators of sample purity. Color of 
chromatograph peaks correspond to specific nucleotides: cytosine (blue), guanosine (black), 
adenosine (green), and thymine (red). Red boxes highlight the amino acid substitution caused 
by the specific nucleotide substitution.  
  
 62 
7. UM42811 affects the dimer/oligomer conformation of NS3/4A 
heterodimers 
 
Because BRET infers PPIs based on eYFP and Rluc dipole proximity with an optimal 
resolution at 10–100 Å range, distances created by conformational changes and those created 
from PPI abolishment are somewhat ambiguous. To see whether UM42811 induced any 
quantitative changes in the NS3/4A heterodimeric homodimer, co-immunoprecipitation 
experiments were carried out using NS3/4A constructs fused with different tags. HEK 293T 
cells were co-transfected with NS3/4A constructs N-terminally tagged with either eYFP or 
FLAG and treated with increasing concentrations of UM42811 or in combination with 
protease inhibitor BILN2061. 48 hours post-transfection, cells were lysed and co-
immunoprecipitation using anti-FLAG coated beads was performed. Western blot analysis 
(Figure 10) demonstrated no significant quantitative change in the interaction between FLAG-
tagged NS3 (lower NS3 band) and eYFP-tagged NS3 (upper NS3 band) at any of the 
UM42811 concentrations when compared to a DMSO treated control. Because uninhibited 
NS3/4A is capable of cleaving itself which explains the presence of NS3 bands at lower 
molecular weight when not treated with BILN2061, NS3 immunoblot also demonstrated that 
UM42811 is unable to inhibit NS3/4A protease activity neither in wild type or mutated 
enzymes. Moreover, increasing UM42811 treatment concentrations did not result in any 
change in dimerization/oligomerization in wild type enzyme. Interestingly, putative resistance 
point mutations L14F, I615M, and K617N do not show any effect on the enzyme’s 
autoprotease activity, but appear to result in hindered dimerization/oligomerization. This is 
demonstrated by the fainter eYFP-tagged NS3 immunoprecipitate bands presented in the lanes 
with the mutated enzyme. Though the upper NS3 bands in the mutated enzyme lanes of the 
lysate panel indicate slightly lower expression of eYFP-tagged NS3, it is not sufficient to 
explain the stark quantitative difference between eYFP-tagged NS3 immunoprecipitate bands 
in wild type vs mutated enzymes. Supplemental data using untreated controls would be 
required to ascertain and better describe the latter observation. Furthermore, the more 
pronounced eYFP-tagged NS3 band found in samples treated with BILN2061 when compared 
to a DMSO treated control showed that NS3-NS3 interactions were more significant in its 
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heterodimeric precursor form (NS3/4A) than its mature cleaved form (NS3).  A reduction in 
heterodimeric precursor form interaction was observed when samples were treated with 
UM42811. Though this observation requires a replicate experiment to confirm its robustness it 
may also be a reflection of the effect of UM42811 on the precursor’s putative host interactions 
later discussed in results section 9-10.  
 
The results from UM42811 treatment on wild type NS3/4A combined with BRET 
titration data suggest that the inhibitory mechanism of UM42811 involves a conformational 
change in NS3/4A-NS3/4A PPI. Moreover, resistance mutations conferring a handicapped 
dimerization/oligomerization agrees with an inhibitory mechanism which involves PPI 
tightening. Finally, the potency of UM42811 in inhibiting HCV replication despite its null 
effect on enzymatic activity suggests that the tightening conformation of these NS3/4A 
dimers/oligomers may hide sites for important downstream interactions.  
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Figure 10. Point mutations at putative resistant sites of UM42811 may affect the 
NS3/4A heterodimeric homodimers  - UM42811binding reduces precursor interaction 
induced by BILN2061   
HEK 293T cells were transfected with the indicated expression vectors and treated 
with the indicated concentration of BILN2061 and/or UM42811. 48 post-transfection, cells 
were harvested and co-IP using anti-FLAG coated beads was performed on cell lysates. 
Interaction between molecular weight distinguishable NS3/4A fusion constructs was resolved 
by immunoblot.  
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8. Functional consequences of a UM42811/BILN2061-sensitive 
NS3/4A-KPNB1 interaction 
 
The contribution of NS3/4A to the viral lifecycle is not restricted to polyprotein 
processing alone. As demonstrated by previous results, UM42811 inhibits viral replication 
without affecting protease activity though resistance profiling and initial screening methods 
suggest NS3/4A to be the most probable target. Much like how the restoration of innate 
immunity through preventing the cleavage of type I IFN potentiators MAVS (91) and TRIF 
(92) is a contributor to the antiviral effect of protease inhibitors, contributors to the alternative 
inhibitory mechanism of UM42811 may be found in other previously identified unique 
NS3/4A host interactors (95). Among novel interactors, nucleocytoplasmic transporter 
karyopherin/importin subunit beta 1 (KPNB1/IMPβ1) was found to strongly associate with 
NS3/4A and shown, in a follow-up study on viral subversion mechanisms (253), to be 
implicated in antiviral signaling. Part of the data demonstrated that silencing KPNB1 in either 
HEK 293T or A549 cells negatively impacted ISG56 expression in favour of viral protein 
production following Sendai virus (SeV) infection (Figure 11A - highlighted version of 
original data (253)). At 8 hours post-infection, both HEK 293T and A549 cells knocked down 
for KPNB1 showed no expression of ISG56 while SeV proteins were expressed when 
compared to a non-target transduced control. At 24 hours post-infection, only A549 cells 
which are known to respond more rapidly than HEK 293T cells, showed restored ISG56 
expression. SeV protein expression was also increased in both cell lines when compared to a 
non-target transduced control. Given the impact of KPNB1 silencing on antiviral priming, co-
immunoprecipitation with FLAG-tagged NS3/4A was performed to validate the previously 
identified interaction (Figure 11B). Indeed, immunoblots confirmed the NS3/4A-KPNB1 
interaction, but more interestingly, revealed the appearance of a lower secondary KPNB1 band 
not present in a eYFP transfected control. To further characterize the interaction between 
NS3/4A and KPNB1, co-immunoprecipitation experiments were performed with conditions 
which included BILN2061 and UM42811 treatment (Figure 11C). Surprisingly, both 
compounds at their given concentrations were capable of completely inhibiting the interaction 
though only BILN2061 treatment was associated with the disappearance of the lower 
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secondary KPNB1 band. Taken together, NS3/4A interacts with nucleocytoplasmic transporter 
KPNB1 in a dynamic which can be disrupted by either protease inhibitor BILN2061 or 
compound UM42811.  
 
Knowing the inherent enzymatic activity of HCV NS3/4A, validation of its interaction 
with KPNB1 by Western blot analysis increased the significance of the band of slightly lower 
molecular weight recognized by KPNB1 specific antibodies (Figure 11B). The disappearance 
of this band following treatment with protease inhibitor BILN2061 also contributed to its 
interest (Figure 11C). To explore the possibility of NS3/4A mediated cleavage, the amino acid 
sequence of human encoded KPNB1 was aligned with the reported consensus sequence 
Asp/Glu-(Xaa)4-Cys/Thr ↓ Ser/Ala-(Xaa)2-Leu/Trp/Tyr of NS3/4A cleaved junctions found 
within the HCV polyprotein (118). An amino acid sequence found at the C-terminal end of 
KPNB1 was found to be concordant with the aforementioned consensus sequence (Figure 
12A). The predicted size of fragments generated by such a cleavage also agrees with the 
molecular weights of bands observed in Western analysis (97kDa for full-length KPNB1 vs 
89kDa for C-terminally cleaved KPNB1). Interestingly, cleavage at this site would also occur 
within HEAT repeat 18 of KPNB1 which is absolutely required for its association with 
importin α-5 (also known as KPNA1) (254). The NS3/4A-mediated cleavage of KPNB1 could 
therefore have deleterious effects on nucleocytoplasmic transport (255) and more specifically 
on the nuclear cytoplasmic transport of its notable STAT1 cargo (256). KPNB1 silencing data 
(Figure 11A) and previous data which indicated that the presence of NS3/4A, but not its 
mature NS3 form, was responsible for the prevention of STAT1 nuclear localization upon 
IFN-α stimulation (95) are also consistent with a KPNB1 cleavage narrative. Given STAT1’s 
role in the type I IFN amplification loop (257), and the previously documented effect of 
NS3/4A on its nuclear localization, functional assays using a luciferase reporter under the 
control of an ISRE promoter and IFN-α 2a stimulation were performed to confirm NS3/4A’s 
effect on abrogating type I IFN receptor signaling (Figure 12B). Inhibition of NS3/4A’s 
protease activity through BILN2061 treatment completely restored IFN-α mediated ISG56 
induction (left panel Figure 8B). KPNB1 silencing demonstrated a greater negative effect on 
ISG56 induction than NS3/4A expression (middle panel Figure 12B). The lack of and additive 
negative effect of KPNB1 silencing and NS3/4A ectopic expression on ISG56 induction 
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suggests that NS3/4A mediates inhibition of ISG56 induction through KPNB1. Interestingly, 
while UM42811 inhibits NS3/4A’s interaction with KPNB1 (Figure 11C), it neither eliminates 
the emergence of C-terminally cleaved KPNB1 nor restores ISG56 induction (right panel 
Figure 12B). Altogether, NS3/4A protease activity prevents IFN-α 2a mediated ISG56 
induction within a KPNB1 dependent pathway possibly by mediating KPNB1 cleavage and 
generating a C-terminal truncated form that leads to the prevention of STAT1 nuclear 
translocation.  
 
The phenotype within the early innate response upon SeV infection of UM42811-
mediated inhibition of the KPNB1-NS3/4A interaction has not yet been investigated. When 
bound to NS3/4A, c-terminally truncated KPNB1 is speculated to play a role in gating HCV 
proteins in the membranous web during replication. This could potentially explain the 
submicromolar antiviral activity of UM42811 in HCV replicon positive cells. On the other 
hand, the toxicity of UM42811 in the 10-20 uM range is believed to be due to a trans-
dominant negative effect of truncated KPNB1. This cleaved form of the protein could 
outcompete its native uncleaved form by associating with proteins which would otherwise 
require transport for key cellular processes.  
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Figure 11. NS3/4A interacts with KPNB1, but is disrupted by both UM42811 and the 
protease inhibitor BILN2061. 
(A) HEK 293T (left) and A549 (right) are transduced with shNT or shKPNB1 for 3 
days and infected with SeV for 8 or 24 hours. KPNB1, ISG56, SeV protein expression are 
resolved by immunoblot. (B) HEK 293T cells were transfected with an 3xFLAG-NS3/4A 
expression vector. 48 post-transfection, cells were harvested and co-IP using anti-FLAG 
coated beads was performed on cell lysates. Interaction between NS3/4A and KPNB1 was 
resolved by immunoblot. (C) HEK 293T cells were transfected with an 3xFLAG-NS3/4A 
expression vector and treated with the indicated concentration of BILN2061 or UM42811. 48 
post-transfection, cells were harvested and co-IP using anti-FLAG coated beads was 
performed on cell lysates. Interaction between NS3/4A and KPNB1 was resolved by 
immunoblot.  
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Figure 12. NS3/4A protease activity is required for the inhibition of KPNB1-mediated 
ISG56 induction following IFN-α 2A stimulation. 
(A) Cartoon representation of a potential NS3/4A protease cleavage site on KPNB1. 
(B) HEK 293T cells were transduced with a KPNB1 shRNA for 72 hours (middle panel); 
transfected with an ISG56-luciferase reporter, a renilla luciferase reporter (for normalization) 
and indicated expression vectors; treated with either 1µM BILN2061 (left panel) or 10µM 
UM42811 (right panel) as indicated for 48 hours; and stimulated with IFN-α 2A for 24 hours. 
Luciferase fold intensity was measured and compared with control cells transduced with a 
non-target shRNA (middle panel) or with 0.5% DMSO treated empty vector transfected 
control cells (left and right panels). 
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9. Differential HSP60-IRF3-NS3/4A interaction configurations 
under UM42811 or BILN2061 treatment 
 
Because Gene Ontology enrichment of specific HCV-host interactors yielded protein 
transport as the top hit with a large contribution from NS3/4A (95), the potential implication 
of chaperonins in the inhibitory mechanism of UM42811 was also explored. Chaperones 
constitute an important group of host cytoprotective molecules and are involved in protein 
folding, multimeric protein assembly, protein trafficking, and protein degradation (258).  An 
interaction with mitochondrial heat shock protein 60 (HSP60), also known as HSPD1, is 
interesting not only given its possible involvement in shuttling NS3/4A to host immune factors 
such as MAVS, but also for its possible involvement in converting enzymes to their active 
state as is the case for the HBV polymerase (259). Moreover, HSP60 was previously shown to 
be directly implicated in apoptotic processes with important implications in tumorigenesis 
(260) and was shown to interact, in independent instances, with other viral factors like HCV 
core (261) and hepatitis B X protein (HBx) (262) in various apoptotic processes. More 
recently, HSP60 was shown to be implicated in type I IFN induction through its interaction 
with the pathway’s key transcription factor IRF3(263). With these functional implications in 
mind, further characterization of the HSP60-NS3/4A interaction was sought to provide 
insights towards potential immune dampening/subversion mechanisms which could be 
possibly be altered by UM42811 treatment. To this end, co-immunoprecipitation experiments 
were performed with FLAG-tagged NS3/4A and reciprocally with FLAG-tagged HSP60 and 
eYFP-tagged NS3/4A in HEK 293T cells to validate the reported interactions between 
NS3/4A, HSP60 and IRF3 by Western blot analysis (Figure 13A-B). Indeed, immunoblots in 
both instances confirmed the NS3/4A-HSP60 interaction. Similar to previous experiments 
with KPNB1, to further characterize the interaction with HSP60, co-immunoprecipitation 
experiments were performed with the inclusion of BILN2061 and UM42811 treatment 
conditions (Figure 13C-D). Unlike the interaction with KPNB1, only UM42811 at 10 μM 
concentration was capable of inhibiting this interaction. Interestingly, HSP60’s interaction was 
preferential to NS3/4A in its immature precursor form as demonstrated by the BILN2061 
treated sample (Figure 13D).   
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Immunoblots also confirmed the previously reported interaction between HSP60 and 
IRF3 (Figure 13D) while demonstrating in an independent instance that NS3/4A interacted 
with IRF3 (Figure 13C). These interactions were, however, differentially affected by treatment 
with either UM42811 or protease inhibitor BILN2061 (Figure 13C-D). While the NS3/4A-
IRF3 interaction was disrupted by UM42811 treatment, the HSP60-IRF3 interaction was 
disrupted by BILN2061 treatment. This suggests that IRF3 and HSP60 preferentially interact 
with precursor NS3 than with each other if the UM42811-induced tightening of the NS3/4A 
oligomer is assumed to preclude these interactions, and if NS3 is assumed to exist in its 
mature and precursor forms in similar biological proportions without BILN2061 treatment 
(Figure 15B). These results also indicate that the presence of specific viral factors such as 
NS3/4A is a prerequisite for the HSP60-IRF3 interaction. How the expression of a single viral 
enzyme is distinguished from its endogenously expressed counterparts is still unknown. It can 
be speculated that the HSP60-IRF3 interaction is a stress response triggered upon pathogenic 
or non-homeostatic levels of enzymatic activity. 
 
Because HSP60’s contribution to type I IFN signalling could have further implications 
for HSP60’s interaction with NS3/4A, functional assays using a luciferase reporter under the 
control of an IFN-β promoter and SeV stimulation were performed to verify HSP60’s effect on 
IFN-β induction (Figure 14). Surprisingly, unlike reports by Lin et al. (263) contribution to 
type I IFN signaling was not reflected by IFN-β induction with quantitative changes of HSP60 
expression whether silenced or overexpressed. As readout time points differ (8 vs 24 hours 
post-infection), the differences in IFN-β induction may reflect a temporal sensitization 
wherein HSP60 is not the limiting factor. When evaluated at 24 hours post-infection, any 
effect observed on IFN-β induction was negligible when compared to the negative impact 
observed with NS3/4A ectopic expression. The negative impact of NS3/4A expression on 
IFN-β induction following SeV infection is likely a reflection of the effect of MAVS cleavage 
on type I IFN production. Taken together, NS3/4A interacts with HSP60 in a dynamic which 
is disrupted by UM42811, but that is unlikely to have a significant bearing on IFN-β induction 
at 24 hours post SeV infection based on lack of effect induced by quantitative changes in 
HSP60 expression. 
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Figure 13. NS3/4A interacts with HSP60, but is disrupted by UM42811. 
(A) HEK 293T cells were transfected with an 3xFLAG-NS3/4A expression vector. 48 
post-transfection, cells were harvested and co-IP using anti-FLAG coated beads was 
performed on cell lysates. Interaction between NS3/4A and HSP60 was resolved by 
immunoblot. (B) HEK 293T cells were co-transfected with an eYFP-NS3/4A and a FLAG-
HSP60 expression vector. 48 post-transfection, cells were harvested and co-IP using anti-
FLAG coated beads was performed on cell lysates. Interaction between NS3/4A, HSP60 was 
resolved by immunoblot. (C) HEK 293T cells were transfected with an 3xFLAG-NS3/4A 
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expression vector and treated with the indicated concentration of BILN2061 or UM42811. 48 
post-transfection, cells were harvested and co-IP using anti-FLAG coated beads was 
performed on cell lysates. Interaction between NS3/4A and HSP60 or IRF3 was resolved by 
immunoblot. (D) HEK 293T cells were transfected with an eYFP-NS3/4A and a FLAG-
HSP60 expression vector and treated with the indicated concentration of BILN2061 or 
UM42811. 48 hours post-transfection, cells were harvested and co-IP using anti-FLAG coated 
beads was performed on cell lysates. Interaction between HSP60 and NS3/4A or IRF3 was 
resolved by immunoblot.  
 
Figure 14. Quantitative changes in HSP60 expression have no effect on IFN-𝛽 
induction following SeV infection. 
HEK 293T cells were transduced with a HSP60 shRNA for 72 hours; transfected with 
an IFN-β-luciferase reporter, a renilla luciferase reporter (for normalization) and NS3/4A and 
HSP60 expression vectors as indicated for 48 hours; and infected with SeV for 24 hours. 
Luciferase fold intensity was measured and compared with control cells transduced with a 
non-target shRNA (left) or with empty vector transfected control cells (right). 
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Figure 15. Hypothesized interaction configuration between NS3, HSP60 and IRF3 in 
the context of UM42811 and BILN2061 treatment 
(A) Compiled co-immunoprecipitation experiments from Figures 6, 13C and 13D to 
facilitate the rationalization of interaction changes between NS3, HSP60 and IRF3. (B) Table 
denoting pairwise interactions observed in co-immunoprecipitation experiments. Cartoon 
visualization of the different hypothesized interaction configurations assuming protein 
interactions are dependent on the precursor form of NS3. Represented are NS3 (beige), NS4A 
(yellow), HSP60 (green), and IRF3 (blue).  
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Discussion 
 
Initiated from the same screening method designed to characterize the pairwise 
interaction network within the HCV proteome, the characterization of UM42811, an HCV 
antiviral compound identified amongst approximately 110,000 others as an NS3/4A-NS3/4A 
interaction modulator, is owed to an adapted high throughput BRET screening method. This 
approach was elected after careful consideration of its advantages and limitations. Notably, 
this technology is capable of providing information of specific interacting protein regions 
applicable in live cells and in membrane bound complexes. It does however have certain 
limitations associated with the use of tags and the distinction of conformational changes from 
PPI disengagement. The BRET signal and the intensity of BRETmax are function of the 
distance and consequently of the orientation between dimer partners and can provide 
information not only about protein interactions but about specific regions mediating this 
interaction. For example, the BRETmax of NS5A homodimerization was strong when the 
energy donor Rluc and the energy acceptor eYFP were N-terminally tagged whereas C-
terminally tagged NS5A proteins were characterized by relatively weak BRETmax (232). This 
observation is supported by earlier reports that NS5A proteins interact via their N-terminal 
domain I (264). Moreover, the sensitivity of BRET allows utility beyond resolving PPIs to be 
extracted from the technique. In some instances, both extremities of a protein were tagged to 
determine conformational changes induced by substrate binding through intramolecular BRET 
signals (265). BRET, as a non-radioactive energy transfer technique, also has the benefit of 
being compatible with live cell settings. It can therefore be used to determine PPIs with more 
confidence as it can more easily reflect what occurs naturally within a cell. It also represents 
an unprecedented method to observe membrane PPIs as more elaborate studies involving 
crystal structures requires soluble forms of the proteins of interest.  In other words, membrane 
PPIs inferred from crystal structures may not be as biologically relevant. For instance, studies 
involving HCV NS proteins often required the removal of membrane anchoring regions 
despite these regions being necessary for proper formation of the iconic HCV multimeric 
replication complex (266). The strength of BRET is that it can be applied to any membrane 
bound protein interaction, and not exclusively for those involved with HCV, in a biologically 
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relevant setting which is otherwise not possible. In the previous report where novel HCV 
protein interactions were identified (232), the inclusion of the interaction between NS4B and 
NS5A, which are located at the ER and at LDs respectively, and the exclusion of the 
interaction between NS3/4A and p7, which are both localized to the mitochondria, within an 
updated HCV interaction network attest for the specificity of BRET and its independence from 
protein localization. The technique is not without its pitfalls however, the requirement of a 
eYFP and a Rluc tag carries with it a number of assumptions. These tags are quite sizeable 
relative to other tags and their use assumes that they have a negligible impact on the native 
conformation, localization, function and dynamic of a protein. For example, a C-terminal 
tagging of the NS3/4A heterodimer could severely influence its mitochondrial localization as 
NS4A is responsible for membrane anchoring (116). These considerations are only amplified 
as the size of the tagged protein decreases. The use of BRET in identifying or characterizing 
PPIs also requires certain knowledge of the investigated proteins. As with previously 
mentioned examples, because of the sensitivity of BRET, an improper management of the 
localizations of donor and acceptor tags can yield false negatives.  
 
Though not without contradicting evidence (267), it has previously been shown that the 
helicase domain of NS3 could dimerize and that dimerization was required for its enzymatic 
activity (268). The cysteine protease activity of NS2/3 was also shown to require dimerization 
(269). Because the enzymatic activity of NS2/3 precedes that of NS3/4A in polyprotein 
processing, this also implies an instance of polyprotein dimerization and by extension a 
potential key determinant for NS3/4A dimerization in generating the NS2/3 active site. There 
is still no real consensus on exactly how the NS3 helicase functions though it has been 
suggested that relative enzyme to substrate concentrations are the determinant factor (115). 
Nevertheless, Figure 5 demonstrates the dimerization of the NS3/4A in cellulo. Taken together 
with the UM42811-mediated BRET induced signal activation of protease inactive S139A 
NS3/4A mutant (Figure 7B); the greater significance of the precursor NS3/4A band particular 
to BILN2061 treated samples in co-immunoprecipitation experiments (Figure 10); the reduced 
co-immunoprecipitation of BILN 2061-mediated precursor NS3/4A-NS3/4A interaction 
(Figure 10 ), the homodimerization of the NS3/4A heterodimer appears to be more significant 
than that of NS3 in the replicative cycle of HCV. Considering many viral proteases (270) and 
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even HCV NS2/3 protease (269) were shown to require dimerization for enzymatic activity, it 
would be interesting to determine whether dimerization of the NS3/4A heterodimer is also 
required for its protease activity. Answering this question, however, would require 
supplementary tools as the distinction between conformational changes and specific protein 
interaction disengagement is not fully addressed with BRET-based assays alone as 
demonstrated by BILN2061 treatment in BRET titration experiments (Figure 7B) and NS3/4A 
co-immunoprecipiration experiments (Figure 10). 
HCV therapeutics has been quickly evolving over the last decade. Most successful 
DAAs currently target the NS3/4A serine protease, NS5B polymerase or the mechanistically 
elusive NS5A. Interestingly, the discovery of NS5A inhibitors came through fortuitous HTS 
with inhibitory effect achieved through the apparent influence of compounds on the NS5A 
dimer interaction (164, 166). Though the specific role of the homodimeric NS3/4A-NS3/4A 
interaction was not fully characterized within the HCV lifecycle prior to initiating BRET 
based compound screening, the homology found in the discovery and mechanism of NS5A 
inhibitors provided a level of confidence in the identification of novel anti-HCV agents.  
 
Being positively evaluated based on statistical Z’ and Z factors of each interaction 
configuration (Figure 6B) (245), the implementation of BRET based HTS of small molecule 
compounds successfully illustrated the potential of BRET not only in the assessment of 
membrane PPIs, but also in its adaptability for large scale drug discovery programs. To 
account for readout artefacts and partly as a secondary consequence of being undistinguishable 
from cytotoxic effect, compound selection based on bioluminescence quenching was set at a 
liberal <95% cutoff. For logistics purposes, all compounds were tested at 10 µM 
concentrations in the primary screen. As a consequence of incidental cytotoxicity below 10 
µM, certain compound hits may have been false positives. These concerns were pre-emptively 
addressed with the implementation of a secondary screen and downstream antiviral 
characterization of individual hits. Out of approximately 110,000 compounds, 110 hits were 
identified representing a global hit rate of 0.10% for the primary BRET HTS assay, which was 
considered satisfactory.   
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 Confirmation of primary screen hits in a replicate experiment, hit validation via dose-
response analyses reporting antiviral potency and cytotoxicity (Figure 7C) and hit specificity 
confirmation via BRET titration  (right panel Figure 7B) and resistance mapping (Figure 8B-
C) ultimately cements BRET as a valid and attractive HTS method through the discovery and 
characterization of UM42811. The therapeutic index within Huh7 cells bearing subgenomic 
Con1 replicon determined at 48.05 was relatively favorable when compared to compounds 
identified in a similar anti-HCV HTS (271). In the assay designed by Yu et al., approximately 
2,000 compounds were screened for their effectiveness against every stage of infection using 
cell culture-derived HCV at low multiplicities of infection and averaged a therapeutic index of 
roughly 16 within its 18 or so hits. Moreover, because amino acid sequence alignment for 
weighing potential resistance mutations used a compiled database of full-length HCV 
genomes indiscriminate of genotype, concerns of antiviral potency being skewed towards a 
specific genotype were lessened. It is important to recognize, however, that the use of an 
infectious model for HCV replication could have potentially yielded very different therapeutic 
indices considering NS3/4A has also been shown to affect the assembly phases of the viral 
lifecycle (81, 272, 273). Cytotoxicity is also susceptible to some variation depending on the 
cell type used to report it but cytotoxicity assays using hepatocyte cell lines are considered a 
good model for primary hepatocytes.  
 
As antiviral compounds apply extreme selective pressures on virus replication, the 
recurrence of specific escape mutations under such pressure is undeniably highly informative 
in a compound’s binding site. Ultimately, the mapping of resistance mutations provides strong 
insights towards a compound’s target. In this regard, the surface localization of both I615M 
and K617N on the C-terminal helicase subdomain added more feasibility to their identity as 
potential resistance mutations; these sites were rather accessible and could very well have 
been involved in PPIs. Furthermore, the substitution of lysine to asparagine at position 617 of 
NS3 constituted a loss of a positive charge and could have seriously altered interactions at this 
site. Interestingly, although L14F was not weighted heavily based on naturally occurring 
sequence variation, its localization at the putative alpha helix of the protease domain which is 
involved in the membrane anchoring of the NS3/4A complex was functionally relevant. 
Because of the unique structural features of NS3/4A that defines its relatively featureless 
 79 
substrate binding cleft (110), HCV protease inhibitors are often restricted in their core designs 
and are consequently characterized by nearly identical resistance profiles. Mutations occurring 
at V36, T54, V55, Q80, R155, A156, D168, and V170 can occur naturally and have been 
verified in replicon studies to be associated with protease inhibitor resistance (248, 249). With 
these factors considered, escape variants characterized by mutations occurring within NS3/4A, 
but outside of the aforementioned sites would have been indicative of a novel inhibitory 
mechanism independent of protease inhibition. 
The affect that UM42811 has on PPIs involving NS3/4A is quite striking. The 
disruption of the NS3/4A-KPNB1 (Figure 11C), NS3/4A-HSP60 and NS3/4A-IRF3 (Figure 
13C) interactions by UM42811 in conjunction with a potential stabilization of either a mature 
or precursor NS3/4A-NS3/4A dimer (left panel Figure 7B) suggest that a tighter NS3/4A-
NS3/4A homodimer conformation prevents host interactors from associating with the complex 
(Figure 15). On the other hand, the lack of any effect on self-cleavage (Figure 10) and weak 
effect on KPNB1 cleavage (Figure 11C) suggests that formation of a tighter dimer does not 
influence its protease activity. Because the reduced cleavage on KPNB1 that is derived from 
the consensus sequence found at NS3/4A-cleaved junctions within the HCV polyprotein 
(Figure 12A), it is also possible that this putative conformational tightening affects polyprotein 
processing and explain submicromolar antiviral activity of UM42811.  
Despite resistance mutations attributing different binding locations for either 
compound, the inhibition of the NS3/4A-KPNB1 interaction by both UM42811 and 
BILN2061 coupled with the inhibition of the NS3/4A-HSP60 and the NS3/4A-IRF3 
interactions only by UM42811 suggests KPNB1 interacts with NS3/4A via two distinct sites; 
the protease active site which contains an overlap with the binding site for UM42811, HSP60 
and IRF3 and a site only inaccessible in tightly bound NS3/4A homodimers. Moreover, 
because both BILN2061 and UM42811 inhibit the NS3/4A-KPNB1 interaction (Figure 11C) 
though only BILN2061 is able to restore KPNB1 mediated ISG56 induction (Figure 12B), the 
NS3/4A protease activity can specifically be inferred to be responsible for ISG56 induction 
inhibition via the cleavage of the nucleocytoplasmic transporter KPNB1 and thereby the 
prevention STAT1 nuclear translocation.  
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Interestingly, the potential capacity of NS3/4A to cleave KPNB1 presents functional 
implications within innate immunity reminiscent to the characterized cleavage of MAVS (91) 
and TRIF (92). To expand, KPNB1 requires association with its partner KPNA1 for 
nucleocytoplasmic transport of its cargo (255). STAT1, which is implicated in the JAK/STAT 
pathway of type I IFN signalling, is a major KPNB1 cargo (256). Because the potential 
NS3/4A mediated cleavage site occurs within a region of KPNB1 absolutely required for its 
association with KPNA1 (254), the effect on innate immunity is a definite possibility.  
As chaperones are involved in numerous biological functions related to protein 
turnover and transport (258), the NS3/4A-HSP60 interaction is interesting given its possible 
involvement in shuttling NS3/4A to host immune factors such as MAVS, and also for its 
possible involvement in converting enzymes to their active state as is the case for the HBV 
polymerase (259). Given HSP60’s involvement in apoptotic processes (260) and type I IFN 
signalling (263), the NS3/4A-HSP60 interaction also provides other unclear biological 
implications. Interestingly, the presence of NS3/4A seemed to be required for the HSP60-IRF3 
interaction described by Lin et al. (263) to occur. Why the expression of a viral enzyme is a 
prerequisite or rather how the expression of a single viral enzyme is distinguished from its 
endogenously expressed counterparts is still unknown. It can be speculated that the HSP60-
IRF3 interaction is a stress response triggered upon pathogenic or non-homeostatic levels of 
enzymatic activity. Continuing with the HSP60-IRF3 interaction, when NS3/4A was present, 
this interaction was disrupted by BILN2061 treatment (Figure 13D). This suggests that IRF3 
and HSP60 preferentially interact with precursor NS3 than with each other if the UM42811-
induced tightening of the NS3/4A oligomer is assumed to preclude NS3/4A-HSP60 and 
NS3/4A-IRF3 interactions, and if NS3/4A is assumed to exist in its mature and precursor 
forms in similar biological proportions without BILN2061 treatment (Figure 15B).  
  
 81 
Perspectives 
 
 
Site directed mutagenesis within the subgenomic Con1 replicon would yield variants 
which contain punctual mutations with the highest potential to confer UM42811 resistance. 
Introduction of these mutations both alone and in combination will allow the validation of 
these mutations as resistance bearing and provide further confirmation of UM48211’s target 
and proposed mechanism. This would entail site directed mutagenesis within the replicon 
system, in vitro transcription reactions to generate proper RNA transcripts, electroporation or 
adapted transfections to introduce HCV RNA into replication-permissive Huh7.5 cells, and 
finally, dose-response analysis to evaluate shifts relative to wild type in EC50 that would 
correspond to resistance. Given that resistance mapping and the original screening method 
responsible for UM42811’s identification are coherent with a novel inhibitory mechanism, it is 
expected that atypical L14F, I615M, and K617N mutations confer resistance to UM42811 at 
least to varying degrees. An indirect approach based on the mutated enzymes alone could also 
provide further insights towards resistance. Performing BRET titration curves with mutated 
enzymes would show whether native NS3/4A dimer/oligomer conformation is impaired and 
whether UM42811 treatment no longer induces dimer/oligomer conformational tightening. 
The differential interaction configurations induced by UM42811 and BILN 2061 treatment 
could also be reevaluated in the context of individual mutated enzymes. Striking differences 
between these configurations with wild type versus mutated NS3/4A would be informative not 
only mechanistically for UM42811 but also for NS3/4A’s host interaction network.  
 
The relationship between HCV NS3/4A protease and nucleocytoplasmic transport 
factor KPNB1 and its potential involvement in immune evasion remains to be elucidated. 
Verification that KPNB1 cleavage is directly mediated by NS3/4A at biologically relevant 
concentrations and not a by-product of another undefined mechanism derived from the 
protease activity of NS3/4A is the first step. To this end, generation of KPNB1 variants, one 
substituting the cleavage essential P1 cysteine and one truncated from the P1 site onwards, in 
conjunction with silencing of endogenous KPNB1 could be used to verify NS3/4A mediated 
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cleavage and its functional derivatives. The C-terminally truncated KPNB1 could also be used 
to verify, simply by its ectopic expression, whether it facilitates HCV replication or it has a 
dominant negative effect on full-length KPNB1 nuclear transport function. The latter could 
demonstrate whether the NS3/4A-KPNB1 interaction which is abrogated at 10 uM is a 
secondary cytotoxic effect to UM42811’s HCV replication inhibition. The setup would entail 
PCR reactions for site directed mutagenesis or insertion of a premature stop codon, lentiviral 
silencing to eliminate confounding factors in downstream analysis and transfection of 
silencing resistant KPNB1 variant expression vectors into either replicon bearing or NS3/4A 
expressing cells. Assuming tags do not significantly alter its properties, C-terminal tagging of 
these variants could also be used to increase the resolution with which full-length and cleaved 
KPNB1 are distinguished. Downstream analysis would involve NS3/4A co-
immunoprecipitation to verify whether truncated KPNB1 binds NS3/4A in a manner similar to 
N-terminal product inhibitors, western blot analysis to evaluate KPNB1 cleavage, and either 
IFN-α stimulation or SeV/HCV infection in immunocompetent reporter cells to evaluate the 
outcome of KPNB1 cleavage protection on innate immune priming. If NS3/4A truly mediates 
the cleavage of KPNB1, C-terminally truncated and not full-length KPNB1 would be expected 
to be the predominant NS3/4A interactant, P1 cysteine substituted KPNB1 would be expected 
to present a single unique band in Western analysis, and a functional restoration would be 
expected for conditions using the P1 cysteine substituted KPNB1 variant. C-terminally 
truncated KPNB1 could also be particularly useful, in co-immunoprecipitation experiments, to 
confirm whether its association with KPNA1 is truly abrogated (or if it facilitate HCV 
replication in KPNB1 KD cells bearing the HCV replicon). The NS3/4A-HSP60 interaction 
presented unclear implications in type I IFN signaling. To reconcile discrepancies with 
reported literature (263), a kinetic experiment with time points between 8 and 24 hours post 
SeV infection could be used to evaluate whether HSP60-facilitated IFN-β induction is truly a 
temporal sensitization. As MAVS is cleaved by NS3/4A (91) and as HSP60 is an important 
mitochondrial chaperone involved in protein trafficking, observing a moderate decrease in 
NS3/4A-dependent MAVS cleavage upon HSP60 knockdown could be used to verify whether 
HSP60 plays a role in shuttling NS3/4A to MAVS. 
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Conclusion 
 
  By exploiting membrane protein-protein interactions, live cell assays using BRET 
technology have been optimized to complete a comprehensive HCV protein interaction 
network. Using the experience gained from this study, an HTS cell-based assay was 
implemented to identify novel inhibitory compounds targeting an unreported NS3/4A-NS3/4A 
interaction. Approximately 110,000 compounds from a small-molecule collection were 
screened to monitor modulation of NS3/4A homodimerization and were discriminated based 
on specificity and potency. UM42811 was identified as a potential activator of the NS3/4A-
NS3/4A interaction and demonstrated promising antiviral activity with an excellent 
therapeutic window. Resistance studies and parallel interaction studies were initiated to 
characterize the novel inhibitory mechanism of UM42811. 
 
In conclusion, combined deep sequencing and mutation mapping have yielded a 
resistance profile based on statistical and functional probability for novel small-molecule 
antiviral UM42811. This resistance profile coupled with the original screening method pointed 
towards a novel inhibitory mechanism targeting HCV NS3/4A serine protease. Previous 
interaction network studies, functional assays and western analysis confirmed novel NS3/4A 
host interactants KPNB1 and HSP60 with varying implications within cell biology. These 
interactions were disrupted by UM42811 treatment. NS3/4A-mediated cleavage of KPNB1 
was briefly explored and had significant repercussions on the type I IFN innate immune 
priming. While most HCV drug campaigns have been discontinued with treatment regimens 
largely covered by current combination therapies, the cost of these therapies still hinder their 
widespread use. Chemical optimization of UM42811 could prove to yield a less costly 
alternative that could be used in combination with protease inhibitors. Nevertheless, the 
characterization of a lead compound emerging from PPI assays in live cells definitely 
demonstrates the potential of creative screening design in drug discovery campaigns with 
applications that go beyond the scope of HCV.    
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Annex 1: Spliceosome SNRNP200 Promotes Viral RNA 
Sensing and IRF3 Activation of Antiviral Response. 
 
This annex is to state that I contributed to the paper "Spliceosome SNRNP200 
Promotes Viral RNA Sensing and IRF3 Activation of Antiviral Response." by Tremblay 
et al., published in the peer-reviewed open-access journal "PLOS Pathogens" in July 2016. As 
secondary co-author, I performed experiments to address issues in previous revisions 
(unpublished), contributed to the overall flow and clarity of explanations and had meaningful 
input in the design of figures, particularly Figure 3 and Figure 10.  
 i 
 
 ii 
Annex 2: HCV NS3/4A Protease Inhibitors and the Road to 
Effective Direct-Acting Antiviral Therapies. 
 
This annex is to state that I contributed to the review chapter "HCV NS3/4A Protease 
Inhibitors and the Road to Effective Direct-Acting Antiviral Therapies." by Tremblay et 
al., that will be published in the Springer Japan book "Hepatitis C Virus II: Infection and 
Disease" by Miyamura et al. expected later in 2016. As secondary co-author, I contributed to 
the overall flow and clarity of the text as well as verified coherence with updated patent 
literature.
  
 
